EP1628654A2 - Verbindungen und verfahren zur abgabe von prostacyclin-analoga - Google Patents

Verbindungen und verfahren zur abgabe von prostacyclin-analoga

Info

Publication number
EP1628654A2
EP1628654A2 EP04776104A EP04776104A EP1628654A2 EP 1628654 A2 EP1628654 A2 EP 1628654A2 EP 04776104 A EP04776104 A EP 04776104A EP 04776104 A EP04776104 A EP 04776104A EP 1628654 A2 EP1628654 A2 EP 1628654A2
Authority
EP
European Patent Office
Prior art keywords
compound
treprostinil
groups
group
esters
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP04776104A
Other languages
English (en)
French (fr)
Other versions
EP1628654A4 (de
EP1628654B2 (de
EP1628654B1 (de
Inventor
Ken Phares
David Mottola
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United Therapeutics Corp
Original Assignee
United Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34079029&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1628654(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by United Therapeutics Corp filed Critical United Therapeutics Corp
Priority to EP14162471.8A priority Critical patent/EP2792353B1/de
Publication of EP1628654A2 publication Critical patent/EP1628654A2/de
Publication of EP1628654A4 publication Critical patent/EP1628654A4/de
Application granted granted Critical
Publication of EP1628654B1 publication Critical patent/EP1628654B1/de
Publication of EP1628654B2 publication Critical patent/EP1628654B2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/125—Saturated compounds having only one carboxyl group and containing ether groups, groups, groups, or groups
    • C07C59/13—Saturated compounds having only one carboxyl group and containing ether groups, groups, groups, or groups containing rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C07C59/70—Ethers of hydroxy-acetic acid, e.g. substitutes on the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/708—Ethers
    • C07C69/712—Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings

Definitions

  • This invention pertains generally to prostacyclin analogs and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis.
  • the compounds of the present invention may be used in the treatment of/for: pulmonary hypertension, ischemic diseases (e.g., peripheral vascular disease, Raynaud's phenomenon, Scleroderma, myocardial ischemia, ischemic stroke, renal insufficiency), heart failure (including congestive heart failure), conditions requiring anticoagulation (e.g., post Mb post cardiac surgery), thrombotic microangiopathy, extracorporeal circulation, central retinal vein occlusion, atherosclerosis, inflammatory diseases (e.g., COPD, psoriasis), hypertension (e.g., preeclampsia), reproduction and parturition, cancer or other conditions of unregulated cell growth, cell/tissue preservation and other emerging therapeutic areas where prostacyclin treatment appears to have a beneficial role.
  • ischemic diseases e.g., peripheral vascular disease, Raynaud's phenomenon, Scleroderma, myocardial ischemia, ischemic stroke, renal insufficiency
  • treprostinib a chemically stable analog of prostacyclin.
  • Remodulin® Food and Drug Administration
  • treprostinil as the free acid has an absolute oral bioavailability of less than 10%. Accordingly, there is clinical interest in providing treprostinil orally.
  • FDA Food and Drug Administration
  • the present invention provides a compound having structure I:
  • R 1 is independently selected from the group consisting of H, substituted and unsubstituted benzyl groups, and groups wherein OR are substituted or unsubstituted glycolamide esters; 7 R" and R may be the same or different and are independently selected from the group consisting of H. phosphate and groups wherein OR and OR form esters of amino acids or proteins, with the proviso that all of R 1 , R 2 and R 3 are not H; an enantiomer of the compound; and pharmaceutically acceptable salts of the compound and polymorphs.
  • R 1 is a substituted or unsubstituted benzyl group, such as CH 2 C 6 H 5 .
  • OR 1 is a substituted or unsubstituted glycolamide ester
  • R 1 is -CH 2 CONR 4 R 5
  • R 4 and R 5 may be the same or different and are independently selected from the group consisting of H, OH, substituted and unsubstituted alkyl groups, -(CH 2 ) m CH 3 , -CH 2 OH, and -CH 2 (CH 2 ) n OH, with the proviso that m is 0, 1, 2, 3 or 4, and n is 0, 1, 2, 3 or 4.
  • one or both of R 4 and R 5 are independently selected from the group consisting of H, -OH, -CH 3 , or -CH 2 CH 2 OH.
  • R 2 and R 3 can be H.
  • R and R are independently selected from phosphate and groups wherein OR and OR are esters of amino acids, dipeptides, esters of tripeptides and esters of tetrapeptides. hi some compounds only one of R orR is a phosphate group.
  • OR 2 and OR 3 are esters of amino acids, such as esters of glycine or alanine.
  • one of R 2 and R 3 are H.
  • the oral bioavailability of the compound is greater than the oral bioavailability of treprostinil, such as at least 50% or 100% greater than the oral bioavailability of treprostinil.
  • the above compounds can further comprise an inhibitor of p-glycoprotein transport. Any of these compounds can also further comprise a pharmaceutically acceptable excipient.
  • the present invention also provides a method of using the above compounds therapeutically of/for: pulmonary hypertension, ischemic diseases, heart failure, conditions requiring anticoagulation, thrombotic microangiopathy, extracorporeal circulation, central retinal vein occlusion, atherosclerosis, inflammatory diseases, hypertension, reproduction and parturition, cancer or other conditions of unregulated cell growth, cell/tissue preservation and other emerging therapeutic areas where prostacyclin treatment appears to have a beneficial role.
  • a preferred embodiment is a method of treating pulmonary hypertension and/or peripheral vascular disease in a subject comprising orally administering a pharmaceutically effective amount of a compound of structure II:
  • R 1 is independently selected from the group consisting of H, substituted and unsubstituted alkyl groups, arylalkyl groups and groups wherein OR 1 form a substituted or unsubstituted glycolamide ester;
  • R 2 and R 3 may be the same or different and are independently selected from the group consisting of H, phosphate and groups wherein OR 2 and OR 3 form esters of amino acids or proteins, with the proviso that all of R 1 , R 2 and R 3 are not H; an enantiomer of the compound; and a pharmaceutically acceptable salt or poiymorph of the compound.
  • R 1 when OR 1 forms a substituted or unsubstituted glycolamide ester, R 1 is -CH 2 CONR 4 R 5 , wherein R 4 and R 5 may be the same or different and are independently selected from the group consisting of H, OH, substituted and unsubstituted alkyl groups, -(CH 2 ) m CH 3 , -CH 2 OH, and - CH 2 (CH 2 ) n OH, with the proviso that m is 0, 1, 2, 3 or 4, and n is 0, 1, 2, 3 or 4.
  • R 1 is a C ⁇ -C alkyl group, such as methyl, ethyl, propyl or butyl.
  • R 1 can also be a substituted or unsubstituted benzyl group, hi other methods, R 1 can be -CH 3 or -CH 2 C 6 Hs.
  • R 4 and R 5 are the same or different and are independently selected from the group consisting of H, OH,
  • R and R 3 are H.
  • R 2 and R 3 are independently • 9 " selected from phosphate and groups wherein OR and OR are esters of amino acids, dipeptides, esters of tripeptides and esters of tetrapep tides. In some methods, only one of R 2 or R 3 is a phosphate group.
  • R 2 and R 3 are • 9 ⁇ independently selected from groups wherein OR and OR are esters of amino acids, 1 9 such as esters of glycine or alanine.
  • one of R and R is H.
  • the oral bioavailability of the compound is greater than the oral bioavailability of treprostinil, such as at least 50% or 100% greater than the oral bioavailability of treprostinil.
  • the present methods can also comprise administering pharmaceutically effective amount of a p-glycoprotein inhibitor, simultaneously, sequentially, or prior to administration of the compound of structure II.
  • the p-glycoprotein inhibitor is administered orally or intravenously.
  • the disclosed methods can be used to treat pulmonary hypertension.
  • the present invention also provides a method of increasing the oral bioavailability of treprostinil or pharmaceutically acceptable salt thereob comprising administering a pharmaceutically effective amount of a p-glycoprotein inhibitor and orally administering a pharmaceutically effective amount of treprostinil to a subject.
  • the p-glycoprotein inhibitor is administered prior to or simultaneously with the treprostinil.
  • the route of the p-glycoprotein inhibitor administration can vary, such as orally or intravenously.
  • the present invention also provides a composition comprising treprostinil or a pharmaceutically acceptable salt thereof and a p-glycoprotein inhibitor.
  • the present compound can also be administered topically or transdermally.
  • Pharmaceutical formulations according to the present invention are provided which include any of the compounds described above in combination with a pharmaceutically acceptable carrier. The compounds described above can also be used to treat cancer. Further objects, features and advantages of the invention will be apparent from the following detailed description.
  • Figures 1 A and IB respectively show plasma concentration versus time curves for intravenous and intraportal dosing of treprostinil diethanolamine salt in rats as described in Example 1;
  • Figures 2A, 2B and 2C respectively show plasma concentration versus time curves for intraduodenab intraco Ionic and oral dosing of treprostinil di ethanol amine salt in rats as described in Example 1 ;
  • Figure 3 shows on a logarithmic scle the average plasma concentration versus time curves for the routes of administration described in Example 1 ;
  • Figure 4 is a graphical representation of the plasma concentration versus time curve for treprostinil in rat following oral administration in rats of treprostinil methyl ester as described in Example 2;
  • Figure 5 is a graphical representation of the plasma concentration versus time curve for treprostinil in rat following oral administration in rats of treprostinil benzyl ester as described in Example 2;
  • Figure 6 is
  • Figure 8 is a graphical representation of the plasma concentration versus time curve for treprostinil in rat following intraduodenal administration of treprostinil monophosphate (ring) as described in Example 3;
  • Figure 9 is a graphical representation of the plasma concentration versus time curve for treprostinil in rat following intraduodenal administration of treprostinil mono valine (ring) as described in Example 3;
  • Figure 10 is a graphical representation of the plasma concentration versus time curve for treprostinil in rat following intraduodenal administration of treprostinil monoalanine (ring) as described in Example 3;
  • Figure 11 is a graphical representation of the plasma concentration versus time curve for treprostinil in rat following intraduodenal administration of treprostinil monoalanine (chain) as described in Example 3;
  • Figure 12 is a graphical representation of the avergage plasma concentration versus time curve for each prodrug compared
  • Figure 14 shows pharmacokinetic profiles of UT-15C sustained release tablets and sustained release capsules, fasted and fed state.
  • Figure 15 shows an X ray powder diffraction spectrum of the polymorph Form
  • Figure 16 shows an IR spectrum of the polymorph Form A.
  • Figure 17 shows a Raman spectrum of the polymorph Form A.
  • Figure 18 shows thermal data of the polymorph Form A.
  • Figure 19 shows moisture sorption data of the polymorph Form A.
  • Figure 20 shows an X ray powder diffraction spectrum of the polymorph Form
  • Figure 21 shows thermal data of the polymorph Form B.
  • Figure 22 shows moisture sorption data of the polymorph Form B.
  • the present invention provides compounds and methods for inducing prostacyclin-like effects in a subject or patient.
  • the compounds provided herein can be formulated into pharmaceutical formulations and medicaments that are useful in the methods of the invention.
  • the invention also provides for the use of the compounds in preparing medicaments and pharmaceutical formulations and for use of the compounds in treating biological conditions related to insufficient prostacyclin activity as outlined in the Field of Invention.
  • the present invention also provides compounds and methods for the treatment of cancer and cancer related disorders.
  • the present compounds are chemical derivatives of (+)- treprostinil. which has the following structure:
  • Treprostinil is a chemically stable analog of prostacyclin, and as such is a potent vasodilator and inhibitor of platelet aggregation.
  • the sodium salt of treprostinil, (lR,2R,3aS,9aS)-[[2,3,3a,4,9,9a -Hexahydro-2-hydroxy -l-[(3S)-3- hydroxyoctyl]-lH-benz[fJinden-5-yl] oxyjacetic acid monosodium salt is sold as a solution for injection as Remodulin® which has been approved by the Food and Drug Administration (FDA) for treatment of pulmonary hypertension, hi some embodiments, the present compounds are derivatives of (-)-treprostinib the enantiomer of (+)-treprostinib
  • a preferred embodiment of the present invention is the diethanolamine salt of treprostinib
  • the present invention further includes polymorphs of the above compounds,
  • a particularly preferred embodiment of the present invention is form B of treprostinil diethanolamine.
  • the present compounds are generally classified as prodrugs of treprostinil that convert to treprostinil after administration to a patient, such as through ingestion.
  • the prodrugs have little or no activity themselves and only show activity after being converted to treprostinib
  • the present compounds were produced by chemically derivatizing treprostinil to make stable esters, and in some instances, the compounds were derivatized from the hydroxyl groups.
  • Compounds of the present invention can also be provided by modifying the compounds found in U.S. Patent Nos. 4,306,075 and 5,153,222 in like manner.
  • the present invention provides compounds of structure I:
  • R is independently selected from the group consisting of H, substituted and unsubstituted benzyl groups and groups wherein OR 1 are substituted or unsubstituted glycolamide esters;
  • R 2 and R 3 may be the same or different and are independently selected from the group consisting of H, phosphate and groups wherein OR 2 and OR 3 form esters of amino acids or proteins, with the proviso that all of R 1 , R 2 and R 3 are not H; enantiomers of the compound; and pharmaceutically acceptable salts of the compound.
  • R 1 is -CH 2 CONR 4 R 5 and R 4 and R 5 may be the same or different and are independently selected from the group consisting of H, OH, substituted and unsubstituted alkyl groups, -(CH 2 ) m CH 3 , -CH 2 OH, and -CH 2 (CH 2 ) n OH, with the proviso that m is 0, 1, 2, 3 or 4, and n is 0, 1, 2, 3 or 4.
  • R 1 can specifically exclude H, substituted and unsubstituted benzyl groups, or groups wherein OR 1 are substituted, or unsubstituted glycolamide esters.
  • R 1 is a substituted or unsubstituted benzyl groups, such as -CH 2 C 6 H 5 , -CH 2 C 6 H 4 NO 2 , -CH 2 C 6 H 4 OCH 3 , -CH 2 C 6 H 4 Cb -CH 2 C 6 H 4 (NO 2 ) 2 , or - CH 2 C 6 H 4 F.
  • the benzyl group can be ortho, meta, para, ortho/para substituted and combinations thereof.
  • Suitable substituents on the aromatic ring include halogens (fluorine, chlorine, bromine, iodine), -NO 2 groups, -OR 16 groups wherein R 16 is H or a C ⁇ -C 4 alkyl group, and combinations thereof.
  • R 4 and R 5 may be the same or different and are independently selected from the group consisting of H, OH, -CH 3 , and - CH 2 CH 2 OH.
  • R is not H, generally one or both of R and
  • R 3 are H.
  • R 1 is -CH 2 CONR 4 R 5
  • R 4 and R 5 are H, -OH, -CH 3 , -CH 2 CH 2 OH.
  • R 2 and R 3 can be independently selected from phosphate and groups wherein OR 2 and OR 3 are esters of amino acids, dipeptides, esters of tripeptides and esters of tefrapeptides. hi some 9 "-. embodiments, only one of R or R is a phosphate group. In compounds where at least one of R 2 and R 3 is not H, generally R 1 is H.
  • R 2 and R 3 are H and thus the compound of structure I is derivatized at only one of R 2 and R 3 .
  • R 2 is H and R 3 is defined as above.
  • R 1 and R 3 are H and R 2 is a group wherein OR 2 is an ester of an amino acid or a dipeptide.
  • R 1 and R 2 are H and R 3 is a group wherein OR 3 is an ester of an amino acid or a dipeptide.
  • OR 2 and OR 3 groups form esters of amino acids or peptides, i.e., dipeptides, tripeptides or tefrapeptides, these can be depicted generically as -COCHR 6 NR 7 R 8 wherein R 6 is selected from the group consisting of amino acid side chains, R and R may be the same or different and are independently selected from the group consisting of H, and -COCHR 9 NR 10 R n .
  • reference to amino acids or peptides refers to the naturally occurring, or L-isomer, of the amino acids or peptides.
  • D-isomer amino acid residues can take the place of some or all of L- amino acids.
  • mixtures of D- and L-isomers can also be used.
  • R 7 together with R 6 forms a pyrrolidine ring structure.
  • R 6 can be any of the naturally occurring amino acid side chains, for example -CH 3 (alanine), -(CH 2 ) 3 NHCNH 2 NH (arginine), -CH 2 CONH 2 (asparagine), -CH 2 COOH (aspartic acid,), -CH 2 SH (cysteine), -(CH 2 ) 2 CONH 2 (glutamine), -(CH 2 ) 2 COOH (glutamic acid), -H (glycine), -CHCH 3 CH 2 CH 3 (isoleucine), -CH 2 CH(CH 3 ) 2 (leucine), -(CH 2 ) 4 NH 2 (lysine), -(CH 2 ) 2 SCH 3 (methionine), -CH2Ph (phenylalanine), -CH 2 OH (serine), -CHOHCH 3 (threonine), - CH(CH 3 ) 2 (valine), (histidine), (tryptophan), and
  • R and R may be the same or different and are selected from the group consisting of H, and -COCHR 9 NR 10 R ⁇ , wherein R 9 is a side chain of amino acid, R 10 and R 1 may be the same or different and are selected from the group consisting of H, and -COCHR 12 NR 13 R 14 , wherein R 12 is an amino acid side chain, R 13 and R 14 may be the same or different and are independently selected from the group consisting of H, and -COCHR 15 NH 2 .
  • the peptide chains can be extended on the following scheme to the desired length and include the desired amino acid residues.
  • OR 2 and OR 3 groups form an ester of a peptide, such as dipeptide, tripeptide, tetrapeptide, etc.
  • the peptides can be either homopeptides, i.e., repeats of the same amino acid, such as arginyl-arginine, or heteropeptides, i.e., made up of different combinations of amino acids.
  • heterodipeptides include alanyl-glutamine, glycyl-glutamine, lysyl-arginine, etc.
  • R 7 and R 8 when only one R 7 and R 8 includes a peptide bond to further amino acid, such as in the di, tri and tefrapeptides, the resulting peptide chain will be linear. When both R 7 and R 8 include a peptide bond, then the peptide can be branched.
  • R is H and one of R or R 3 is a phosphate group or H while the other R 2 or R 3 is a group such the OR 2 or OR 3 is an ester of an amino acid, such as an ester of glycine or alanine.
  • Pharmaceutically acceptable salts of these compounds as well as pharmaceutical formulation of these compounds are also provided.
  • the compounds described herein have enhanced oral bioavailability compared to the oral bioavailability of treprostinib either in free acid or salt form.
  • the described compounds can have oral bioavailability that is at least 25%, 50% 100%, 200%), 400% or more compared to the oral bioavailability of treprostinib
  • the absolute oral bioavailability of these compounds can range between 10%, 15%, 20%, 25%, 30% and 40%, 45%, 50%, 55%, 60% or more when administered orally.
  • the absolute oral bioavailability of treprostinil is on the order of 10%, although treprostinil sodium has an absolute bioavailability approximating 100% when administered by subcutaneous infusion.
  • the present compounds are well suited for topical or transdermal administration.
  • the above compounds, and in particular the compounds of stracture I are prostacyclin-mimetic and are useful in treating conditions or disorders where vasodilation and/or inhibition of platelet aggregation or other disorders where prostacyclin has shown benefit, such as in treating pulmonary hypertension.
  • the present invention provides methods for inducing prostacyclin-like effects in a subject comprising administering a pharmaceutically effective amount of one or more of the compounds described herein, such as those of structure I above, preferably orally, to a patient in need of such treatment.
  • the vasodilating effects of the present compounds can be used to treat pulmonary hypertension, which result from various forms of connective tissue disease, such as lupus, scleroderma or mixed connective tissue disease. These compounds are thus useful for the treatment of pulmonary hypertension.
  • the present invention also provides methods of promoting prostacyclin-like effect in a subject by administering a pharmaceutically effective amount of a compound of structure II:
  • R 1 is independently selected from the group consisting of H, substituted and unsubstituted alkyl groups, arylalkyl groups and groups wherein OR 1 form a substituted or unsubstituted glycolamide ester;
  • R 2 and R 3 may be the same or different and are independently selected from the group consisting of H, phosphate and groups wherein OR 2 and OR 3 form esters of amino acids or proteins, with the proviso that all of R 1 , R 2 and R 3 are not H; an enantiomer of the compound; and a pharmaceutically acceptable salt of the compound.
  • R 1 can be -CH 2 CONR 4 R 5 , wherein R 4 and R 5 may be the same or different and are independently selected from the group consisting of H, OH, substituted and unsubstituted alkyl groups, -(CH 2 ) m CH 3 , -CH 2 OH, and -CH 2 (CH 2 ) n OH, with the proviso that m is 0, 1, 2, 3 or 4, and n is 0, 1, 2, 3 or 4.
  • R 1 can be a Ci-C 4 alkyl group, such as methyl, ethyl, propyl or butyl.
  • R 1 is a substituted or unsubstituted benzyl groups, such as -CH 2 C 6 H 5 , -CH 2 C 6 H NO 2 , - CH 2 C 6 H 4 OCH 3 , -CH 2 C 6 H 4 Cb -CH 2 C 6 H 4 (NO 2 )2, or -CH 2 C 6 H 4 F.
  • the benzyl group can be ortho, meta, para, ortho/para substituted and combinations thereof.
  • Suitable substituents on the aromatic ring include halogens (fluorine, chlorine, bromine, iodine), -NO2 groups, -OR 16 groups wherein R 16 is H or a C ⁇ -C alkyl group, and combinations thereof.
  • R 1 is -CH 2 CONR 4 R 5 then R 4 and R 5 may be the same or different and are independently selected from the group consisting of H, OH, -CH 3 , and -CH 2 CH 2 OH.
  • R is not H
  • R generally one or both of R and R 3 are H.
  • one or both of R 2 and R 3 are H and R 1 is -CH 3 , -CH 2 C 6 H 5 .
  • R 1 is -CH 2 CONR 4 R 5 , and one or both of R 4 and R 5 are H, -OH, -CH 3 , -CH 2 CH 2 OH.
  • R and R can be independently selected from phosphate and groups wherein OR 2 and OR 3 are esters of amino acids, dipeptides, esters of tripeptides and esters of tefrapeptides. In some embodiments, only one of R 2 or R 3 is a phosphate group. In methods where at least one of R 2 and R 3 is not H, generally R 1 is H.
  • R 2 or R 3 is H and the other R 2 or R 3 is as defined elsewhere herein, i some methods, R 2 is H and R is not H.
  • R and R are H and R is a group wherein OR 2 is an ester of an amino acid or a dipeptide.
  • R 1 and R 2 are H and R 3 is a group wherein OR 3 is an ester of an amino acid or a dipeptide.
  • OR 2 and OR 3 groups form esters of amino acids or peptides, i.e., dipeptides, tripeptides or tefrapeptides
  • these can be depicted generically as -COCHR 6 NR 7 R 8 wherein R 6 is selected from the group consisting of amino acid side chains, R 7 and R 8 maybe the same or different and are independently selected from the group consisting of H, and -COCHR 9 NR 10 R ⁇ .
  • R 7 together with R 6 forms a pyrrolidine ring structure.
  • R can be any of the naturally occurring amino acid side chains, for example -CH 3 (alanine), -(CH 2 ) 3 NHCNH 2 NH (arginine), -CH 2 CONH 2 (asparagine), -CH 2 COOH (aspartic acid,), -CH 2 SH (cysteine), -(CH 2 ) 2 CONH 2 (glutamine), -(CH 2 ) 2 COOH (glutamic acid), -H (glycine), -CHCH 3 CH 2 CH 3 (isoleucine), -CH 2 CH(CH 3 ) 2 (leucine), -(CH 2 ) 4 NH 2 (lysine), -(CH 2 ) 2 SCH 3 (methionine), -CH2Ph (phenylalanine), -CH 2 OH (serine), -CHOHCH 3 (threonine), - CH(CH 3 ) 2 (valine),
  • R 7 and R 8 may be the same or different and are selected from the group consisting of H, and -COCHR 9 NR 10 R ⁇ , wherein R 9 is a side chain of amino acid, R 10 and R 11 may be the same or different and are selected from the group 19 1 T 1 - .
  • R and R 14 may be the same or different and are independently selected from the group consisting of H, and -COCHR 15 NH 2 .
  • the peptide chains can be extended on the following scheme to the desired length and include the desired amino acid residues.
  • OR 2 and OR 3 groups form an ester of a peptide, such as dipeptide, tripeptide, tetrapeptide, etc.
  • the peptides can be either homopeptides, i.e., repeats of the same amino residue, or heteropeptides, i.e., made up of different combinations of amino acids.
  • R 1 is H and one of R 2 or R 3 is a phosphate group or H while the other R 2 or R 3 is a group such the OR 2 or OR 3 is an ester of an amino acid, such as an ester of glycine or alanine.
  • the administered compound can have an oral bioavailability that is at least 25%, 50% 100%, 200%, 400% of the oral bioavailability of treprostinib It is generally preferred to administer compounds that have higher absolute oral bioavailabilities, such as 15%, 20%, 25%, 30% and 40%, 45%, 50%, 55%, 60% or more when administered orally.
  • Treprostinil has also been discovered to inhibit metastasis of cancer cells as disclosed in U.S. Patent Application Serial No. 10/006,197 filed December 10, 2001 and Serial No. 10/047,802 filed January 16, 2002, both of which are hereby incorporated into this application.
  • the compounds described above, and in particular those of stracture I and LT can also be used in the treatment of cancer and cancer related disorders, and as such the present invention provides pharmaceutical compositions and methods for treating cancer.
  • Suitable formulations and methods of using the present compounds can be achieved by substituting the compounds of the present invention, such as those of stracture I and II and in particular prodrugs of treprostinib for the active compounds disclosed in U.S. Patent Application Serial Nos. 10/006,197 and 10/047,802 filed January 16, 2002.
  • Synthesis of the following compounds of structure I and structure II can be achieved as follows:
  • Methyl ester of treprostinil (2) was prepared by treating 1.087 g (2.8 mrholes) of treprostinil (1) with 50 ml of a saturated solution of dry hydrochloric acid in methanol. After 24 hours at room temperature, the methanol was evaporated to dryness and the residue was taken in 200 ml dichloromethane. The dichloromethane solution was washed with a 10% aqueous potassium carbonate solution, and then with water to a neutral pH, it was dried over sodium sulfate, filtered and the solvent was removed in vacuo affording treprostinil methyl ester (2) in 98% yield as a yellow oil. The crude methyl ester was used as such in subsequent reactions.
  • the aqueous-methanolic solution was concentrated almost to dryness in vacuo, water was added and the solution was extracted with n-butanol (3 x 10 ml), then with methylene chloride (1 x 10 ml).
  • the pH of the solution was adjusted to 9.0 by treatment with a sulfonic acid ion exchange resin (H+ cycle - Dowex); treatment with Dowex resin for a longer time (— 12 hours) lead to both the cleavage of the TBDMS group and the recovery of the free carboxyl group.
  • the resin was filtered and the solution was concentrated to dryness affording the corresponding monophosphate 8 (33 mg, yield 68% > ).
  • Treprostinil acid acid is dissolved in a 1 : 1 molar ratio mixture of ethanol: water and diethanolamine is added and dissolved. The solution is heated and acetone is added as an antisolvent during cooling.
  • ester (11) (0.4 g; 0.51 mmol) in methanol (30 ml) was introduced in the pressure bottle of a Parr hydrogenation apparatus, 10% palladium on charcoal (0.2 g; 0.197 mmol Pd) was added, apparatus closed, purged thrice with hydrogen and loaded with hydrogen at 50 p.s.i. Stirring was started and hydrogenation carried out for 5 hrs. at room temperature. Hydrogen aas removed from the installation by vacuum suction and replaced with argon. The catalyst was filtered off through celite deposited on a fit and the filtrate concentrated in vacuo to give 0.240 g (91%) of 4, white solid m.p. 98-100°C.
  • ester (14) (0.4 g; 0.46 mmol) in methanol (30 ml) was hydrogenated over 10% Pd/C as described for ester (12). Work-up and drying over phosphoras pentoxide in vacuo yielded 0.170 g (72.7%) of ester 15, white solid m.p. 155-158 °C.
  • the crade product is a mixture of the mono-TBDMS (16) and di-TBDMS esters (1H-NMR).
  • Analytical tic on silica gel of the ester 16 showed only one spot (eluent: 3:2 (v/v) hexane-ethyl ether).
  • the mono-OTBDMS ester fractions (45.1%; isolated material) consisted of ester 16 (98%) and its side-chain isomer (2%) that could be distinctly separated; the latter was evidenced (tic, NMR) only in the last of the monoester fractions.
  • ester 16 (0.340 g; 0.57 mmol) in dichloromethane (15 ml) N-carbobenzyloxyglycine p-nitrophenyl ester (0.445 g; 1.35 mmol) and 4-(dimethyamino) pyridine (150 mg; 1.23 mmol) were successively added.
  • the solution was stirred at 20 °C for 40 hrs. Work-up as described for esters 11 and 14 yielded a crade product (0.63 g) containing 90% 17 and 10% 18 (1H-NMR).
  • ester 18 (0.15 g; 0.22 mmol) in methanol (30 ml) was hydrogenated over 10% Pd/C as described for ester 12 and 15. Work-up and drying over phosphoras pentoxide in vacuo yielded ester 10 (0.98 g; 98.0%), white, shiny crystals m.p. 74-76 °C.
  • LR ESI-MS (m/z): 448.2 [M+H] + , 446.4 [M-H] " .
  • ester 16 (0.38 g: 0.64 mmol) and N-carbobenzyloxy-L- leucine N-hydroxysuccinimide ester (0.37 g; 1.02 mmol) in 10 ml dichloromethane 4- (dimethyamino)pyridine (0.17 g; 1.39 mmol) was added, then stirring continued at room temperature for 2 days.
  • the solution was diluted with dichioromethane (40 mnl), successively washed with a 5%> sodium hydroxide solution (4 x 25 ml), 10%> hydrochloric acid (2 x 30 ml), 5% sodium bicarbonate solution (50 ml), dried over anhydrous sodium sulfate and concentrated under reduced pressure to give the crade product (0.85 g), as a viscous, yellow oil.
  • Thin layer chromatography revealed a complex mixture in which esters 13 and 21 as well as cbz-L-leucine could be identified through the corresponding rp values, only as minor products.
  • the crade product was flash-chromatographed through a silica gel column eluting with gradient hexane-ethyl ether. At 7:3 (v/v) hexane-ethyl ether, the first fraction gave the cbz-L- leucyl diester 24 (6% of the product subjected to chromatography) while the two subsequent fractions afforded the cbz-L-leucyl monoester 23 (54% of the crude product, as pure isolated 23; 57.6% yield, relative to 2). Purity of both compounds was verified by analytical tic and NMR. The other isomer, cbz-L-leucyl monoester 21 constituted only about 5% of the crude product and was isolated by preparative tic of the latter only a 3:1 23/21 mixture.
  • the benzyl ester 11 was synthesized by adapting the method described by J. C. Lee et al. in Organic Prep, and Proc. Intl., 1996, 28(4), 480-483. To a solution of 1 (620 mg, 1.6 mmoles) and cesium carbonate (782.4 mg, 2.4 mmoles) in acetonitrile (30 ml) was added benzyl bromide (0.48 ml, 4 mmoles) and the mixture was stirred at reflux for 1 hour. After cooling at room temperature, the precipitate was filtered off and the filtrate was concentrated in vacuo.
  • the residue was dissolved in chloroform (150 ml) and washed with a 2% aqueous solution of NaHCO 3 (3 x 30 ml). The organic layer was washed with brine, dried on Na 2 SO , filtered and the solvent was removed in vacuo to afford 750 mg of the crade benzyl ester 13 (yield 98%) as a yellow viscous oil.
  • the crade benzyl ester 13 can be purified by column chromatography (100-0% dichioromethane(methanol) but it can also be used crade in subsequent reactions.
  • the procedure for the synthesis of the TBDMS protected benzyl ester was adapted from Organic Synth., 1998, 75, 139-145.
  • the benzyl ester 13 (679 mg, 1.4 mmoles) was dissolved in anhydrous dichloromethane (20 ml) and the solution was cooled to 0°C on an ice bath.
  • Imidazole (192 mg, 2.8 mmoles) and t-butyl- dimethylsilyl chloride (TBDMSC1) (420 mg, 2.8 mmoles) were added and the mixture was maintained under stirring for another half hour on the ice bath and then it was left overnight at room temperature.
  • 40 ml water was added to the reaction mixture and the organic layer was separated.
  • the benzyl and benzyl carboxy groups were removed by catalytic hydrogenation at atmospheric pressure in the presence of palladium 10% wt on activated carbon.
  • the 3 '-N-Cbz-L- valine ester of benzyl ester 32 (30.2 mg, 0.04 mmoles) was dissolved in methanol (10 ml) and a catalytic amount of Pd/C was added. Under magnetic stirring the air was removed from the flask and then hydrogen was admitted. The reaction mixture was maintained under hydrogen and stirring at room temperature for 24 hrs, then the hydrogen was removed with vacuum.
  • the filtrate was diluted with dichloromethane (100 ml) and washed with water (3 x 50 ml), a 5%> aqueous acetic acid solution (2 x 50 ml) and then again with water (3 x 50 ml).
  • the organic layer was dried over Na 2 SO 4 and the solvent was evaporated in vacuo affording 556 mg crade product.
  • the product was separated by chromatography (silica gel, 35% ethyl acetate/hexane) yielding 369.4 mg 2-valine ester 34 and 98 mg bis-valine ester 35.
  • the benzyl and benzyl carboxy groups were removed by catalytic hydrogenation at atmospheric pressure in the presence of palladium 10% wt on activated carbon.
  • the 2-N-Cbz-L-valine ester of Treprostinil benzyl ester 34 (58.2 mg, 0.08 mmoles) / bis-N-Cbz-L-valine ester of Treprostinil benzyl ester 35 (55.1 mg, 0.06 mmoles) was dissolved in methanol (10 ml) and a catalytic amount of Pd/C was added. Under magnetic stirring the air was removed from the flask and hydrogen was admitted. The reaction mixture was maintained under hydrogen and stirring at room temperature for 20 hrs, then hydrogen was removed with vacuum.
  • the benzyl and benzyl carboxy groups were removed by catalytic hydrogenation at atmospheric pressure in the presence of palladium 10% wt on activated carbon.
  • the 2-N-Cbz-L-alanine ester of Treprostinil benzyl ester 34' (87.4 mg, 0.13 mmoles) / bis-N-Cbz-L-alanine ester of Treprostinil benzyl ester 35' (135 mg, 0.15 mmoles) was dissolved in methanol (15 ml) and a catalytic amount of Pd/C was added. Under magnetic stirring the air was removed from the flask and hydrogen was admitted.
  • a major barrier to oral delivery for treprostinil is that the compound is susceptible to an efflux mechanism in the gastrointestinal tract.
  • the permeability of treprostinil has been measured across Caco-2 cell monolayers.
  • the apical to basal fransport rate was measured to be 1.39 X 10 6 cm/sec, which is indicative of a highly permeable compound.
  • the basal to apical transport rate was 12.3 X 10 6 cm/sec, which suggests that treprostinil is efficiently effluxed from the serosal to lumenal side of the epithelial cell.
  • the present invention provides pharmaceutical compositions comprising treprostinib the compound of structure I or the compound of stracture lb or their pharmaceutically acceptable salts and combinations thereof in combination with one or more inhibitors of p-glycoprotein.
  • treprostinib the compound of structure I or the compound of stracture lb or their pharmaceutically acceptable salts and combinations thereof in combination with one or more inhibitors of p-glycoprotein.
  • a number of known non-cytotoxic pharmacological agents have been shown to inhibit p-glycoprotein are disclosed in U.S. Patent Nos. 6,451,815, 6,469,022, and 6,171,786.
  • P-glycoprotein inhibitors include water soluble forms of vitamin E, polyethylene glycol, poloxamers including Pluronic F-68, polyethylene oxide, polyoxyethylene castor oil derivatives including Cremophor EL and Cremophor RH 40, Chrysin, (+)-Taxifolin, Naringenin, Diosmin, Quercetin, cyclosporin A (also known as cyclosporine), verapamib tamoxifen, quinidine, phenothiazines, and 9,10- dihydro-5-methoxy-9-oxo-N-[4-[2-(l,2,3,4-tetrahydro-6,7,-dimethoxy-2- isoquinolinyl)ethyl]phenyl]-4-acridinecarboxamide or a salt thereof.
  • Polyethylene glycols are liquid and solid polymers of the general formula H(OCH 2 CH 2 ) n OH, where n is greater than or equal to 4, having various average molecular weights ranging from about 200 to about 20,000. PEGs are also l ⁇ iown as alpha-hydro-omega-hydroxypoly-(oxy-l,2-ethanediyl)polyethylene glycols.
  • PEG 200 is a polyethylene glycol wherein the average value of n is 4 and the average molecular weight is from about 190 to about 210.
  • PEG 400 is a polyethylene glycol wherein the average value of n is between 8.2 and 9.1 and the average molecular weight is from about 380 to about 420.
  • PEG 600, PEG 1500 and PEG 4000 have average values of n of 12.5-13.9, 29-36 and 68-84, respectively, and average molecular weights of 570-630, 1300-1600 and 3000-3700, respectively, and PEG 1000, PEG 6000 and PEG 8000 have average molecular weights of 950-1050, 5400-6600, and 7000-9000, respectively.
  • Polyethylene glycols of varying average molecular weight of from 200 to 20000 are well known and appreciated in the art of pharmaceutical science and are readily available.
  • the preferred polyethylene glycols for use in the instant invention are polyethylene glycols having an average molecular weight of from about 200 to about 20,000.
  • the more preferred polyethylene glycols have an average molecular weight of from about 200 to about 8000. More specifically, the more preferred polyethylene glycols for use in the present invention are PEG 200, PEG 400, PEG 600, PEG 1000, PEG 1450, PEG 1500, PEG 4000, PEG 4600, and PEG 8000. The most preferred polyethylene glycols for use in the instant invention is PEG 400, PEG 1000, PEG 1450, PEG 4600 and PEG 8000.
  • Polysorbate 80 is an oleate ester of sorbitol and its anhydrides copolymerized with approximately 20 moles of ethylene oxide for each mole of sorbitol and sorbitol anhydrides.
  • Polysorbate 80 is made up of sorbitan mono-9-octadecanoate poly(oxy- 1,2-ethandiyl) derivatives. Polysorbate 80, also known as Tween 80, is well known and appreciated in the pharmaceutical arts and is readily available.
  • Water-soluble vitamin E also known as d-alpha-tocopheryl polyethylene glycol 1000 succinate [TPGS] is a water-soluble derivative of natural-source vitamin E. TPGS may be prepared by the esterification of the acid group of crystalline d- alpha-tocopheryl acid succinate by polyethylene glycol 1000. This product is well known and appreciated in the pharmaceutical arts and is readily available. For example, a water-soluble vitamin E product is available commercially from Eastman Corporation as Vitamin E TPGS.
  • Naringenin is the bioflavonoid compound 2,3-dihydro-5,7-dihydroxy-2-(4- hydroxyphenyl) -4H-l-benzopyran-4-one and is also known as 4',5,7- trihydroxyflavanone. Naringenin is the aglucon of naringen which is a natural product found in the fruit and rind of grapefruit. Naringenin is readily available to the public from commercial sources. Quercetin is the bioflavonoid compound 2-(3,4-dihydroxyphenyl)-3,5,7- trihydroxy -4H-l-benzopyran-4-one and is also known as 3,3',4',5,7- pentahydroxyflavone.
  • Quercetin is the aglucon of quercitrin, of rutin and of other glycosides. Quercetin is readily available to the public from commercial sources.
  • Diosmin is the naturally occurring flavonic glycoside compound 7-[[6-O-6- deoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranosyl]oxy]-5-hydroxy-2-(3- hydroxy-4-methoxyphenyl)-4H-l-benzopyran-4-one.
  • Diosmin can be isolated from various plant sources including citras fruits. Diosmin is readily available to the public from commercial sources.
  • Chrysin is the naturally occurring compound 5,7-dihydroxy-2-phenyl-4H-l- benzopyran-4-one which can be isolated from various plant sources. Chrysin is readily available to the public from commercial sources. Poloxamers are alpha-hydro-omega-hydroxypoly(oxyethylene)poly (oxypropylene)poly(oxyethylene) block copolymers. Poloxamers are a series of closely related block copolymers of ethylene oxide and propylene oxide conforming to the general formula HO(C 2 H O) a (C 3 H 6 O) b (C 2 H 4 O) a H.
  • poloxamer 124 is a liquid with “a” being 12, “b” being 20, and having an average molecular weight of from about 2090 to about 2360; poloxamer 188 is a solid with “a” being 80, “b” being 27, and having an average molecular weight of from about 7680 to about 9510; poloxamer 237 is a solid with "a” being 64, “b” being 37, and having an average molecular weight of from about 6840 to about 8830; poloxamer 338 is a solid with "a” being 141, "b” being 44, and having an average molecular weight of from about 12700 to about 17400; and poloxamer 407 is a solid with "a” being 101, "b” being 56, and having an average molecular weight of from about 9840 to about 14600.
  • Poloxamers are well known and appreciated in the pharmaceutical arts and are readily available commercially.
  • Pluronic F-68 is a commercially available poloxamer from BASF Corp.
  • the preferred poloxamers for use in the present invention are those such as poloxamer 188, Pluronic F-68, and the like.
  • Polyoxyethylene castor oil derivatives are a series of materials obtained by reacting varying amounts of ethylene oxide with either castor oil or hydrogenated castor oil. These polyoxyethylene castor oil derivatives are well known and appreciated in the pharmaceutical arts and several different types of material are commercially available, including the Cremophors available from BASF Corporation. Polyoxyethylene castor oil derivatives are complex mixtures of various hydrophobic and hydrophilic components.
  • hydrophobic constituents comprise about 83% of the total mixture, the main component being glycerol polyethylene glycol ricinoleate.
  • Other hydrophobic constituents include fatty acid esters of polyethylene glycol along with some unchanged castor oil.
  • the hydrophilic part of polyoxyl 35 castor oil (17%) consists of polyethylene glycols and glyceryl ethoxylates.
  • polyoxyl 40 hydrogenated castor oil (Cremophor RH 40) approximately 75%o of the components of the mixture are hydrophobic. These comprise mainly fatty acid esters of glycerol polyethylene glycol and fatty acid esters of polyethylene glycol.
  • the hydrophilic portion consists of polyethylene glycols and glycerol ethoxylates.
  • the preferred polyoxyethylene castor oil derivatives for use in the present invention are polyoxyl 35 castor oil, such as Cremophor EL, and polyoxyl 40 hydrogenated castor oil, such as Cremophor RH 40. Cremophor EL and Cremophor RH 40 are commercially available from BASF Corporation.
  • Polyethylene oxide is a nonionic homopolymer of ethylene oxide conforming to the general formula (OCH 2 CH 2 ) n in which n represents the average number of oxyethylene groups. Polyethylene oxides are available in various grades which are well known and appreciated by those in the pharmaceutical arts and several different types of material are commercially available.
  • (+)-Taxifolin is (2R-trans)-2-(3,4-dihydroxyphenyl)-2,3-dihydro-3,5,7- trihydroxy-4H-l -benzo pyran-4-one.
  • Other common names for (+)-taxifolin are (+)- dihydroquercetin; 3,3', 4', 5,7-pentahydroxy-flavanone; diquertin; taxifoliol; and distylin.
  • (+)-Taxifolin is well know and appreciated in the art of pharmaceutical arts and is readily available commercially.
  • the preferred p-glycoprotein inhibitor for use in the present invention are water soluble vitamin E, such as vitamin E TPGS, and the polyethylene glycols.
  • the polyethylene glycols the most preferred p-glycoprotein inhibitors are PEG 400, PEG 1000, PEG 1450, PEG 4600 and PEG 8000.
  • Administration of a p-glycoprotein inhibitor may be by any route by which the p-glycoprotein inhibitor will be bioavailable in effective amounts including oral and parenteral routes. Although oral administration is preferred, the p-glycoprotein inhibitors may also be administered intravenously, topically, subcutaneously, intranasally, rectally, intramuscularly, or by other parenteral routes.
  • an effective p-glycoprotein inhibiting amount of a p-glycoprotein inhibitor is that amount which is effective in providing inhibition of the activity of the p-glycoprotein mediated active transport system present in the gut.
  • An effective p- glycoprotein inhibiting amount can vary between about 5 mg to about 1000 mg of p- glycoprotein inhibitor as a daily dose depending upon the particular p-glycoprotein inhibitor selected, the species of patient to be treated, the dosage regimen, and other factors which are all well within the abilities of one of ordinary skill in the medical arts to evaluate and assess.
  • a preferred amount however will typically be from about 50 mg to about 500 mg, and a more preferred amount will typically be from about 100 mg to about 500 mg.
  • the above amounts of a p-glycoprotein inhibitor can be administered from once to multiple times per day. Typically for oral dosing, doses will be administered on a regimen requiring one, two or three doses per day.
  • a preferred amount will typically be from about 5 mg to about 1000 mg, a more preferred amount will typically be from about 50 mg to about 500 mg, and a further preferred amount will typically be from about 100 mg to about 500 mg.
  • the most preferred amount of water soluble vitamin E or a polyethylene glycol will be from about 200 mg to about 500 mg.
  • water soluble vitamin E or polyethylene glycol can be administered from once to multiple times per day. Typically, doses will be administered on a regimen requiring one, two or three doses per day with one and two being preferred.
  • co-administration refers to administration to a patient of both a compound that has vasodilating and/or platelet aggregation inhibiting properties, including the compounds described in U.S. Patent Nos.
  • 4,306,075 and 5,153,222 which include treprostinil and structures I and II described herein, and a p- glycoprotein inhibitor so that the pharmacologic effect of the p-glycoprotein inhibitor in inhibiting p-glycoprotein mediated fransport in the gut is manifest at the time at which the compound is being absorbed from the gut.
  • the compound and the p-glycoprotein inhibitor may be administered at different times or concurrently.
  • the p-glycoprotein inhibitor may be administered to the patient at a time prior to administration of the therapeutic compound so as to pre-treat the patient in preparation for dosing with the vasodilating compound.
  • vasodilating and/or platelet aggregation inhibiting compounds and the p-glycoprotein inhibitor may be administered essentially concurrently either in separate dosage forms or in the same oral dosage form.
  • the present invention further provides that the vasodilating and/or platelet aggregation inhibiting compound and the p-glycoprotein inhibitor may be administered in separate dosage forms or in the same combination oral dosage form.
  • Co-administration of the compound and the p-glycoprotein inhibitor may conveniently be accomplished by oral administration of a combination dosage form containing both the compound and the p-glycoprotein inhibitor.
  • an additional embodiment of the present invention is a combination pharmaceutical composition for oral administration comprising an effective vasodilating and/or platelet aggregation inhibiting amount of a compound described herein and an effective p-glycoprotein inhibiting amount of a p-glycoprotein inhibitor.
  • This combination oral dosage form may provide for immediate release of both the vasodilating and/or platelet aggregation inhibiting compound and the p-glycoprotein inhibitor or may provide for sustained release of one or both of the vasodilating and/or platelet aggregation inhibiting compound and the p-glycoprotein inhibitor.
  • One skilled in the art would readily be able to determine the appropriate properties of the combination dosage form so as to achieve the desired effect of co-administration of the vasodilating and/or platelet aggregation inhibiting compound and the p- glycoprotein inhibitor.
  • the present invention provides for an enhancement of the bioavailability of treprostinib a drag of stracture I or II, and pharmaceutically acceptable salts thereof by co-administration of a p-glycoprotein inhibitor.
  • a p-glycoprotein inhibitor By co- administration of these compounds and a p-glycoprotein inhibitor, the total amount of the compound can be increased over that which would otherwise circulate in the blood in the absence of the p-glycoprotein inhibitor.
  • co-administration in accordance with the present invention can cause an increase in the AUC of the present compounds over that seen with administration of the compounds alone.
  • bioavailability is assessed by measuring the drag concentration in the blood at various points of time after administration of the drag and then integrating the values obtained over time to yield the total amount of drug circulating in the blood. This measurement, called the Area Under the Curve (AUC), is a direct measurement of the bioavailability of the drag.
  • AUC Area Under the Curve
  • derivatizing treprostinil at the R and R hydroxyl groups can help overcome the barriers to oral treprostinil delivery by blocking these sites, and thus the metabolism rate may be reduced to permit the compound to bypass some of the first pass effect.
  • the prodrag may be actively absorbed from the dipeptide transporter system that exists in the gastrointestinal tract.
  • the present invention provides compounds, such as those found in structures I and II, that reduce the first pass effect of treprostinil and/or reduce the efflux mechanism of the gastrointestinal tract.
  • the subject is a mammal, and in some embodiments is a human.
  • Pharmaceutical formulations may include any of the compounds of any of the embodiments described above, either alone or in combination, in combination with a pharmaceutically acceptable carrier such as those described herein.
  • the instant invention also provides for compositions which may be prepared by mixing one or more compounds of the instant invention, or pharmaceutically acceptable salts thereob with pharmaceutically acceptable carriers, excipients, binders, diluents or the like, to treat or ameliorate a variety of disorders related vasoconstriction and/or platelet aggregation.
  • a therapeutically effective dose further refers to that amount of one or more compounds of the instant invention sufficient to result in amelioration of symptoms of the disorder.
  • the pharmaceutical compositions of the instant invention can be manufactured by methods well l ⁇ iown in the art such as conventional granulating, mixing, dissolving, encapsulating, lyophilizing, emulsifying or levigating processes, among others.
  • compositions can be in the form of, for example, granules, powders, tablets, capsules, syrup, suppositories, injections, emulsions, elixirs, suspensions or solutions.
  • the instant compositions can be formulated for various routes of administration, for example, by oral adrninistration, by transmucosal administration, by rectal administration, transdermal or subcutaneous administration as well as intrathecab intravenous, intramuscular, intraperitoneal, intranasal, intraocular or intraventricular injection.
  • the compound or compounds of the instant invention can also be administered by any of the above routes, for example in a local rather than a systemic fashion, such as injection as a sustained release formulation.
  • dosage forms are given by way of example and should not be construed as limiting the instant invention.
  • powders, suspensions, granules, tablets, pills, capsules, gelcaps, and caplets are acceptable as solid dosage forms. These can be prepared, for example, by mixing one or more compounds of the instant invention, or pharmaceutically acceptable salts thereob with at least one additive or excipient such as a starch or other additive.
  • Suitable additives or excipients are sucrose, lactose, cellulose sugar, mannitob maltitob dextran, sorbitol, starch, agar, alginates, chitins, chitosans, pectins, tragacanth gum, gum arabic, gelatins, coUagens, casein, albumin, synthetic or semi-synthetic polymers or glycerides, methyl cellulose, hydroxypropyhnethyl-cellulose, and/or polyvinylpyrrolidone .
  • oral dosage forms can contain other ingredients to aid in administration, such as an inactive diluent, or lubricants such as magnesium stearate, or preservatives such as paraben or sorbic acid, or anti-oxidants such as ascorbic acid, tocopherol or cysteine, a disintegrating agent, binders, thickeners, buffers, sweeteners, flavoring agents or perfuming agents. Additionally, dyestuffs or pigments may be added for identification. Tablets may be further treated with suitable coating materials known in the art. Additionally, tests have shown that the present compounds, including treprostinib and in particular the compounds of stracture I and II have increased bioavailability when delivered to the duodenum.
  • one embodiment of the present invention involves preferential delivery of the desired compound to the duodenum as well as pharmaceutical formulations that achieve duodenal delivery.
  • Duodenal administration can be achieved by any means known in the art.
  • the present compounds can be formulated in an enteric-coated dosage form.
  • enteric-coated dosage forms are usually coated with a polymer that is not soluble at low pH, but dissolves quickly when exposed to pH conditions of 3 or above. This delivery form takes advantage of the difference in pH between the stomach, which is about 1 to 2, and the duodenum, where the pH tends to be greater than 4.
  • Liquid dosage forms for oral administration may be in the form of pharmaceutically acceptable emulsions, syrups, elixirs, suspensions, slurries and solutions, which may contain an inactive diluent, such as water.
  • Pharmaceutical formulations may be prepared as liquid suspensions or solutions using a sterile liquid, such as, but not limited to, an oil, water, an alcohol, and combinations of these.
  • Pharmaceutically suitable surfactants, suspending agents, emulsifying agents may be added for oral or parenteral administration.
  • suspensions may include oils. Such oil include, but are not limited to, peanut oil, sesame oil, cottonseed oil, corn oil and olive oil.
  • Suspension preparation may also contain esters of fatty acids such as ethyl oleate, isopropyl myristate, fatty acid glycerides and acetylated fatty acid glycerides.
  • Suspension formulations may include alcohols, such as, but not limited to, ethanob isopropyl alcohol, hexadecyl alcohol, glycerol and propylene glycol.
  • Ethers such as but not limited to, poly(ethyleneglycol), petroleum hydrocarbons such as mineral oil and petrolatum; and water may also be used in suspension formulations.
  • Injectable dosage forms generally include aqueous suspensions or oil suspensions which may be prepared using a suitable dispersant or wetting agent and a suspending agent. Injectable forms may be in solution phase or in the form of a suspension, which is prepared with a solvent or diluent. Acceptable solvents or vehicles include sterilized water, Ringer's solution, or an isotonic aqueous saline solution. Alternatively, sterile oils may be employed as solvents or suspending agents.
  • the oil or fatty acid is non-volatile, including natural or synthetic oils, fatty acids, mono-, di- or tri-glycerides.
  • the pharmaceutical formulation may be a powder suitable for reconstitution with an appropriate solution as described above.
  • the formulations may optionally contain stabilizers, pH modifiers, surfactants, bioavailability modifiers and combinations of these.
  • the compounds may be formulated for parenteral administration by injection such as by bolus injection or continuous infusion.
  • a unit dosage form for injection may be in ampoules or in multi-dose containers.
  • pharmaceutically acceptable excipients and carries are generally l ⁇ iown to those skilled in the art and are thus included in the instant invention. Such excipients and carriers are described, for example, in "Remingtons Pharmaceutical Sciences” Mack Pub.
  • the formulations of the invention may be designed for to be short-acting, fast- releasing, long-acting, and sustained-releasing as described below.
  • the pharmaceutical formulations may also be formulated for controlled release or for slow release.
  • the instant compositions may also comprise, for example, micelles or liposomes, or some other encapsulated form, or may be administered in an extended release form to provide a prolonged storage and/or delivery effect. Therefore, the pharmaceutical formulations may be compressed into pellets or cylinders and implanted intramuscularly or subcutaneously as depot injections or as implants such as stents. Such implants may employ l ⁇ iown inert materials such as silicones and biodegradable polymers.
  • a therapeutically effective dose may vary depending upon the route of administration and dosage form.
  • the preferred compound or compounds of the instant invention is a formulation that exhibits a high therapeutic index.
  • the therapeutic index is the dose ratio between toxic and therapeutic effects which can be expressed as the ratio between LD 5 o and ED 50 .
  • the LD 50 is the dose lethal to 50% of the population and the ED 50 is the dose therapeutically effective in 50% of the population.
  • the LD 50 and ED 5 o are determined by standard pharmaceutical procedures in animal cell cultures or experimental animals.
  • a method of preparing pharmaceutical formulations includes mixing any of the above-described compounds with a pharmaceutically acceptable carrier and water or an aqueous solution.
  • Pharmaceutical formulations and medicaments according to the invention include any of the compounds of any of the embodiments of compound of stracture I, II or pharmaceutically acceptable salts thereof described above in combination with a pharmaceutically acceptable carrier.
  • the compounds of the invention may be used to prepare medicaments and pharmaceutical formulations, hi some such embodiments, the medicaments and pharmaceutical formulations comprise any of the compounds of any of the embodiments of the compounds of stracture I or pharmaceutically acceptable salts thereof.
  • the invention also provides for the use of any of the compounds of any of the embodiments of the compounds of stracture I, II or pharmaceutically acceptable salts thereof for prostacyclin-like effects.
  • the invention also provides for the use of any of the compounds of any of the embodiments of the compounds of structure I , II or pharmaceutically acceptable salts thereof or for the treatment of pulmonary hypertension.
  • the invention also pertains to kits comprising one or more of the compounds of stracture I or II along with instructions for use of the compounds, hi another embodiment, kits having compounds with prostacyclin-like effects described herein in combination with one or more p-glycoprotein inhibitors is provided along with instructions for using the kit.
  • kits of the invention may include one or more tablets, capsules, caplets, gelcaps or liquid formulations containing the bioenhancer of the present invention, and one or more tablets, capsules, caplets, gelcaps or liquid formulations containing a prostacyclin-like effect compound described herein in dosage amounts within the ranges described above.
  • Such kits may be used in hospitals, clinics, physician's offices or in patients' homes to facilitate the co- administration of the enhancing and target agents.
  • the kits should also include as an insert printed dosing information for the co-administration of the enhancing and target agents.
  • abbreviations and definitions are used throughout this application: Generally, reference to a certain element such as hydrogen or H is meant to include all isotopes of that element.
  • an R group is defined to include hydrogen or H, it also includes deuterium and tritium.
  • p-glycoprotein inhibitor refers to organic compounds which inhibit the activity of the p-glycoprotein mediated active transport system present in the gut. This transport system actively transports drags which have been absorbed from the intestinal lumen and into the gut epithelium back out into the lumen. Inhibition of this p-glycoprotein mediated active transport system will cause less drug to be transported back into the lumen and will thus increase the net drag transport across the gut epithelium and will increase the amount of drug ultimately available in the blood.
  • oral bioavailability and “bioavailability upon oral administration” as used herein refer to the systemic availability (i.e., blood/plasma levels) of a given amount of drag administered orally to a patient.
  • unsubstituted alkyl refers to alkyl groups that do not contain heteroatoms. Thus the phrase includes straight chain alkyl groups such as methyl, ethyl, propyl, butyl, pentyb hexyb heptyb octyb nonyb decyb undecyb dodecyl and the like.
  • the phrase also includes branched chain isomers of straight chain alkyl groups, including but not limited to, the following which are provided by way of example: -CH(CH 3 ) 2 , -CH(CH 3 )(CH 2 CH 3 ), -CH(CH 2 CH 3 ) 2 , -C(CH 3 ) 3 , -C(CH 2 CH 3 ) 3 , -CH 2 CH(CH 3 ) 2 , -CH 2 CH(CH 3 )(CH 2 CH 3 ), -CH 2 CH(CH 2 CH 3 ) 2 , -CH 2 C(CH 3 ) 3 , - CH 2 C(CH 2 CH 3 ) 3 , -CH(CH 3 )CH(CH 3 )(CH 2 CH 3 ), -CH 2 CH 2 CH(CH 3 ) 2 , - CH 2 CH(CH 3 )(CH 2 CH 3 ), -CH 2 CH 2 CH(CH 3 ) 2 , - CH 2 CH(CH 3 )(CH 2 CH 3
  • the phrase also includes cyclic alkyl groups such as cyclopropyl, cyclobutyb cyclopentyb cyclohexyb cycloheptyb and cyclooctyl and such rings substituted with straight and branched chain alkyl groups as defined above.
  • the phrase also includes polycyclic alkyl groups such as, but not limited to, adamantyl norbornyb and bicyclo[2.2.2]octyl and such rings substituted with straight and branched chain alkyl groups as defined above.
  • the phrase unsubstituted alkyl groups includes primary alkyl groups, secondary alkyl groups, and tertiary alkyl groups.
  • Unsubstituted alkyl groups may be bonded to one or more carbon atom(s), oxygen atom(s), nitrogen atom(s), and/or sulfur atom(s) in the parent compound.
  • Preferred unsubstituted alkyl groups include straight and branched chain alkyl groups and cyclic alkyl groups having 1 to 20 carbon atoms. More preferred such unsubstituted alkyl groups have from 1 to 10 carbon atoms while even more preferred such groups have from 1 to 5 carbon atoms.
  • Most preferred unsubstituted alkyl groups include straight and branched chain alkyl groups having from 1 to 3 carbon atoms and include methyl, ethyl, propyl, and -CH(CH ) 2 .
  • substituted alkyl refers to an unsubstituted alkyl group as defined above in which one or more bonds to a carbon(s) or hydrogen(s) are replaced by a bond to non-hydrogen and non-carbon atoms such as, but not limited to, a halogen atom in halides such as F, Cb Br, and I; and oxygen atom in groups such as hydroxyl groups, alkoxy groups, aryloxy groups, and ester groups; a sulfur atom in groups such as thiol groups, alkyl and aryl sulfide groups, sulfone groups, sulfonyl groups, and sulfoxide groups; a nifrogen atom in groups such as amines, amides, alkylamines, dialkylamines, arylamines, alkylarylamines, diarylamines, N-oxides, imides, and enamines; a silicon atom in groups such as in trialky
  • Substituted alkyl groups also include groups in which one or more bonds to a carbon(s) or hydrogen(s) atom is replaced by a bond to a heteroatom such as oxygen in carbonyb carboxyl, and ester groups; nifrogen in groups such as imines, oximes, hydrazones, and nitriles.
  • Preferred substituted alkyl groups include, among others, alkyl groups in which one or more bonds to a carbon or hydrogen atom is/are replaced by one or more bonds to fluorine atoms.
  • One example of a substituted alkyl group is the trifluoromethyl group and other alkyl groups that contain the trifluoromethyl group.
  • alkyl groups include those in which one or more bonds to a carbon or hydrogen atom is replaced by a bond to an oxygen atom such that the substituted alkyl group contains a hydroxyl, alkoxy, aryloxy group, or heterocyclyloxy group.
  • Still other alkyl groups include alkyl groups that have an amine, alkylamine, dialkylamine, arylamine, (alkyl)(aryl)amine, diarylamine, heterocyclylamine, (alkyl)(heterocyclyl)amine, (aryl)(heterocyclyl)amine, or diheterocyclylamine group.
  • unsubstituted arylalkyl refers to unsubstituted alkyl groups as defined above in which a hydrogen or carbon bond of the unsubstituted alkyl group is replaced with a bond to an aryl group as defined above.
  • methyl (-CH 3 ) is an unsubstituted alkyl group. If a hydrogen atom of the methyl group is replaced by a bond to a phenyl group, such as if the carbon of the methyl were bonded to a carbon of benzene, then the compound is an unsubstituted arylalkyl group (i.e., a benzyl group).
  • the phrase includes, but is not limited to, groups such as benzyl, diphenylmethyl, and 1-phenylethyl (-CH(C 6 H 5 )(CH 3 )) among others.
  • substituted arylalkyl has the same meaning with respect to unsubstituted arylalkyl groups that substituted aryl groups had with respect to unsubstituted aryl groups.
  • a substituted arylalkyl group also includes groups in which a carbon or hydrogen bond of the alkyl part of the group is replaced by a bond to a non-carbon or a non-hydrogen atom.
  • a "pharmaceutically acceptable salt” includes a salt with an inorganic base, organic base, inorganic acid, organic acid, or basic or acidic amino acid.
  • the invention includes, for example, alkali metals such as sodium or potassium; alkaline earth metals such as calcium and magnesium or aluminum; and ammonia.
  • salts of organic bases the invention includes, for example, trimethylamine, triethylamine, pyridine, picoline, ethanolamine, diethanolamine, and triethanolamine.
  • the instant invention includes, for example, hydrochloric acid, hydroboric acid, nitric acid, sulfuric acid, and phosphoric acid.
  • the instant invention includes, for example, formic acid, acetic acid, trifluoroacetic acid, fumaric acid, oxalic acid, lactic acid, tartaric acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid, and p-toluenesulfonic acid.
  • salts of basic amino acids the instant invention includes, for example, arginine, lysine and ornithine.
  • Acidic amino acids include, for example, aspartic acid and glutamic acid.
  • Treating within the context of the instant invention, means an alleviation of symptoms associated with a biological condition, disorder, or disease, or halt of further progression or worsening of those symptoms, or prevention or prophylaxis of the disease or disorder.
  • successful treatment may include a reduction direct vasodilation of pulmonary and/or systemic arterial vascular beds and inhibition of platelet aggregation. The result of this vasodilation will generally reduce right and left ventricular afterload and increased cardiac output and stroke volume. Dose-related negative inofropic and lusifropic effects can also result.
  • treprostinil The bioavailability of treprostinil was evaluated in Sprague-Dawley, male rats. Fifteen surgically modified rats were purchased from Hilltop Lab Animals (Scottdale, PA). The animals were shipped from Hilltop to Absorption Systems' West Chester University facility (West Chester, PA), where they were housed for at least twenty- four hours prior to being used in the study. The animals were fasted for approximately 16 hours prior to dosing. The fifteen rats used in this study were divided into five groups (I, H, IH, IV and N). The weight of the animals and the dosing regimen are presented in Table 1.
  • the dosing solution was prepared by combining 15.2 mg of treprostinil diethanolamine (12.0 mg of the free acid form) with 24 mL of 5%> dextrose. The solution was then sonicated until dissolved for a final concentration of 0.5 mg/mL. The final pH of the dosing solution was 4.6. At the time of dosing, the dosing solution was clear and homogenous.
  • Plasma samples were prepared by solid phase extraction. After an extraction plate was equilibrated, 150 ⁇ L of a plasma sample was placed into the well and vacuumed through. The extraction bed was then washed with 600 ⁇ L of acetonitrile: deionized water (25:75) with 0.2 % formic acid.
  • Mobile Phase Buffer 25 mM NH 4 OH to pH 3.5 w/ 85% formic acid.
  • Reservoir A 10% buffer and 90% water.
  • Reservoir B 10% buffer and 90% acetonitrile.
  • Nebulizing Gas 25 Drying Gas: 60, 350°C Curtain Gas: 25 Ion Spray:
  • FIG. 1 The plasma concentration versus time curves for intravenous, intraportal, infraduodenal, intracolonic and oral dosing are shown in Figures 1 and 2.
  • Figure 3 shows the average plasma concenfration versus time curves for all five routes of RESULTS
  • FIG. 1 The plasma concentration versus time curves for intravenous, intraportal, intraduodenal, intracolonic and oral dosing are shown in Figures 1 and 2.
  • Figure 3 shows the average plasma concentration versus time curves for all five routes of
  • Treprostinil has a terminal plasma half-life of 94 minutes.
  • the distribution phase of treprostinil has a half-life of 10.3 minutes and over 90%> of the distribution and elimination of the compound occurs by 60 minutes post-dosing.
  • the systemic clearance of treprostinil (88.54 mL/min/kg) is greater than the hepatic blood flow signifying that extra-hepatic clearance mechanisms are involved in the elimination of the compound.
  • Treprostinil concenfrations were determined in male Sprague-Dawley rats following a single oral dose of the following compounds:
  • a solution of treprostinil methyl ester was prepared by dissolving 2.21 mg of treprostinil methyl ester with 0.85 mL of dimethylacetamide (DMA). This solution was then diluted with 7.65 mL of PEG 400:Polysorbate 80:Water, 40:1:49. The final concentration of the dosing vehicle was 0.26 mg/mL of treprostinil methyl ester equivalent to 0.25 mg/mL of Treprostinib The dosing vehicle was a clear solution at the time of dosing.
  • DMA dimethylacetamide
  • a solution of treprostinil benzyl ester was prepared by dissolving 2.58 mg of treprostinil benzyl ester with 0.84 mL of dimethylacetamide (DMA). This solution was then diluted with 7.54 mL of PEG 400:Polysorbate 80:Water, 40: 1 :49. The final concentration of the dosing vehicle was 0.268 mg/mL of treprostinil benzyl ester
  • a solution of treprostinil diglycine was prepared by dissolving 1.86 mg of compound with 0.58 mL of dimethylacetamide (DMA). This solution was then diluted with 5.18 mL of PEG 400:Polysorbate 80:Water, 40:1:49. The final concentration of the dosing vehicle was 0.323 mg/mL of treprostinil diglycine equivalent to 0.25 mg/mL of Treprostinib The dosing vehicle was a clear solution at the time of dosing.
  • DMA dimethylacetamide
  • Plasma samples were taken from a jugular vein cannula at the following time points: 0 (pre-dose) 5, 15, 30, 60, 120, 240, 360 and 480 minutes
  • the blood samples were withdrawn and placed into tubes containing 30 ⁇ L of a solution of 500 units per mL of heparin in saline, and centrifuged at 13,000 rpm for 10 minutes.
  • Approximately 200 ⁇ L of plasma was then removed and dispensed into appropriately labeled polypropylene tubes containing 4 ⁇ L of acetic acid in order to stabilize any prodrag remaining in the samples.
  • the plasma samples were frozen at - 20 °C and were transported on ice to Absorption Systems Exton Facility. There they were stored in a -80 °C freezer pending analysis.
  • Plasma samples were analyzed as described in Example 1.
  • Treprostinil was exfracted from the plasma via liquid-liquid extraction then analyzed by LC/MS/MS.
  • the analytical validation results were reported previously in Example 1.
  • the lower limit of quantification (LLOQ) of the analytical method was 0.01 ng/mL. Samples were not assayed for unchanged prodrag.
  • Treprostinil The concentration of Treprostinil at each time point in acidified rat plasma is given in Table 7. Small amounts of Treprostinil appear to be present in the neat compound sample of treprostinil methyl ester and treprostinil diglycine. The concentration of Treprostinil remained constant throughout the course of the experiment, indicating that there was no conversion of prodrag into active compound occurring in acidified plasma.
  • Treprostinil plasma concentrations following administration of treprostinil methyl ester, treprostinil benzyl ester or treprostinil diglycine are shown in Table 8.
  • Figures 4-7 contain graphical representations of the plasma concentration versus time curves for Treprostinil in rat following administration of each prodrag. Table 9 lists each figure and the information displayed.
  • Treprostinil methyl ester resulted in Treprostinil area under the plasma concentration versus time curves (AUCs) less than that after dosing the active compound.
  • Prodrugs treprostinil benzyl ester and treprostinil diglycine both had Treprostinil average AUCs greater than that after dosing of the active compound.
  • Treprostinil diglycine had the highest relative bioavailability of 433% with over 4 times more Treprostinil reaching the systemic circulation.
  • the Cmax following dosing of Treprostinil is 5 ng/mL and occurs only 5 minutes post-dosing.
  • Treprostinil benzyl ester had a relative bioavailability of 226 ⁇ 155 % with a Cmax of 7.2 ng/mL occurring 120 minutes post-dosing. It should also be noted that the AUCs are not extrapolated to infinity.
  • This example illustrates a pharmacokinetic study of treprostinil following administration of a single duodenal dose of treprostinil and various prodrags of the present invention.
  • the area under the curve of Treprostinil in male Sprague-Dawley rats following a single intraduodenal dose of treprostinil monophosphate (ring), treprostinil monovaline (ring), treprostinil monoalanine (ring) or treprostinil monoalanine (chain), prodrags of treprostinil was compared.
  • the compounds were as follows:
  • a dosing solution of treprostinil monophosphate (ring) was prepared by dissolving 1.01 mg of treprostinil monophosphate (ring) in 0.167 mL of dimethylacetamide (DMA) until dissolved. This solution was further diluted with 1.50 mL of PEG 400: Polysorbate 80: Water, 40: 1: 49. The final concentration of the dosing vehicle was 0.603 mg/mL of prodrug equivalent to 0.5 mg/mL of Treprostinib The dosing vehicle was a clear solution at the time of dosing.
  • DMA dimethylacetamide
  • a 50 mg/mL solution of treprostinil monovaline (ring) was prepared in dimethylacetamide (DMA).
  • DMA dimethylacetamide
  • a 25 ⁇ L aliquot of the 50 mg/mL stock solution was then diluted with 175 ⁇ L of DMA and 1.8 mL of PEG 400: Polysorbate 80: Water, 40: 1: 49.
  • the final concentration of the dosing vehicle was 0.625 mg/mL of prodrag equivalent to 0.5 mg/mL of Treprostinib
  • the dosing vehicle was a clear solution at the time of dosing.
  • a solution of treprostinil monoalanine (ring) was prepared by dissolving 1.05 mg of treprostinil monoalanine (ring) in 0.178 mL of dimethylacetamide (DMA) until dissolved. This solution was further diluted with 1.60 mL of PEG 400: Polysorbate 80: Water, 40: 1: 49. The final concentration of the dosing vehicle was 0.590 mg/mL
  • a solution of treprostinil monoalanine (chain) was prepared by dissolving 0.83 mg of treprostinil monoalanine (chain) in 0.14 L of dimethylacetamide (DMA) until dissolved. This solution was further diluted with 1.26 mL of PEG 400: Polysorbate 80: Water, 40: 1: 49. The final concentration of the dosing vehicle was 0.591 mg/mL of treprostinil monoalanine (chain) equivalent to 0.5 mg/mL of Treprostinib The dosing vehicle was a clear solution at the time of dosing.
  • DMA dimethylacetamide
  • Treprostinil The plasma concentrations of Treprostinil following oral administration of each prodrag were evaluated in male Sprague-Dawley rats. Twelve rats were purchased from Hilltop Lab Animals (Scottdale, PA). The animals were shipped from Hilltop to Absorption Systems' West Chester University facility (West Chester, PA). They were housed for at least twenty-four hours prior to being used in the study. The animals were fasted for approximately 1 hours prior to dosing. The twelve rats used in this study were divided into four groups. All groups were dosed on day 1 of the study. The weight of the animals and the dosing regimen are presented in Table 11.
  • This dose of prodrug 0.500 mg/kg oftrepi'ostinil Animals were dosed via an indwelling duodenal cannula. Blood samples were takenfrom a jugular vein cannula at the following time points:0 (pre-dose) 5, 15, 30, 60, 120, 240, 360 and 480 minutes. The blood samples were withdrawn and placed into tubes containing 30 ⁇ L of a solution of 500 units per mL of heparin in saline, and centrifuged at 13,000 rpm for 10 minutes. Approximately 200 ⁇ L of plasma was then removed and dispensed into appropriately labeled polypropylene tubes containing 4 ⁇ L of acetic acid in order to stabilize any prodrug remaining in the samples. The plasma samples were frozen at - 20°C and were transported on ice to Absorption Systems Exton Facility. There they were stored in a -80°C freezer pending analysis.
  • Plasma samples were analyzed using the methods described above.
  • Treprostinil was extracted from the plasma via solid phase extraction then analyzed by LC/MS/MS.
  • the lower limit of quantification (LLOQ) of the analytical method was 0.03 ng/mL.
  • Treprostinil plasma concentrations following administration of treprostinil monophosphate (ring), treprostinil monovaline (ring), freprostinil monoalanine (ring) or treprostinil monoalanine (chain) are shown in Table 12.
  • Figures 8-12 contain graphical representations of the plasma concentration versus time curves for Treprostinil in rat following administration of each prodrug. Table 13 lists each figure and the information displayed.
  • the relative infraduodenal bioavailabilities of four prodrugs of Treprostinil were determined in rats. All the compounds had relative infraduodenal bioavailabilities less than that of the active compound, treprostinil monophosphate (ring) and freprostinil monoalanine (ring) had the highest relative intraduodenal bioavailability at 56% and 38% respectively.
  • the T max for treprostinil monophosphate (ring) and treprostinil monoalanine (chain) occurred 5 minutes post- dosing, treprostinil monovaline (ring) and treprostinil monoalanine (ring) had longer absorption times with T max values of 120 and 60 minutes respectively.
  • Treprostinil concenfrations were highest following freprostinil monophosphate (ring) and treprostinil monoalanine (chain) dosing. They reached approximately 9 ng/mL 5 minutes post-dosing. The bioavailabilities are much greater when dosed intraduodenally than when dosed orally as measured by treprostinil plasma levels.
  • Treprostinil concentrations will be determined in male Sprague-Dawley rats following a single oral or intraduodenal dose of the following compounds of stracture II:
  • Example 81 and the compounds shown in Example 2 and this Example will be administered in close proximity to or simultaneously with various different p-glycoprotein inhibiting compounds at varying concentrations and tested to determine the effect of the p- glycoprotein inhibitors on the oral bioavailability of the compounds.
  • the p- glycoprotein inhibitors will be administered both intravenously and orally.
  • SR sustained release
  • UT-15C treprostinil diethanolamine
  • the first clinical study (01-101) evaluated the ability of escalating doses of an oral solution of UT-15C to reach detectable levels in plasma, potential dose-plasma concentration relationship, bioavailability and the overall safety of UT-15C. Volunteers were dosed with the solutions in a manner that simulated a sustained release formulation releasing drag over approximately 8 hours.
  • the second clinical study assessed the ability of two SR solid dosage form prototypes (i.e., 1. microparticulate beads in a capsule and, 2. tablet) to reach detectable levels in plasma and the potential influence of food on these plasma drag concentrations.
  • the SR prototypes were designed to release UT-15C over approximately an 8 hour time period.
  • UT-15C The oral solution of UT-15C was administered to 24 healthy volunteers to assess the safety and pharmacokinetic profile of UT-15C as well as its bioavailability.
  • Study endpoints included standard safety assessments (adverse events, vital signs, laboratory parameters, physical examinations, and electrocardiograms) as well as pharmacokinetic parameters.
  • Treprostinil plasma concentrations were detectable in all subjects following administration of an oral solution dose of UT-15C. Both AUC; nf and C max increased in a linear fashion with dose for each of the four dose aliquots. The highest concentration observed in this study was 5.51ng/mL after the third 0.25 mg solution dose aliquot of the 2.0 mg UT-15C total dose. Based on historical intravenous treprostinil sodium data, the mean absolute bioavailability values for the 0.2 mg, 0.5 mg, 1.0 mg and 2.0 mg doses of UT-15C were estimated to be 21%, 23%, 24% and 25%, respectively. The results of this study are respectively shown in Figures 13A- 13D.
  • UT-15C was well tolerated by the majority of subjects at all doses given. There were no clinically significant, treatment emergent changes in hematology, clinical chemistry, urinalysis, vital signs, physical exams, and ECGs. The most frequently reported adverse events were flushing, headache, and dizziness.
  • This safety profile with UT-15C (freprostinil diethanolamine) is consistent with the reported safety profile and product labeling of Remodulin (treprostinil sodium) and other prostacyclin analogs. Thus, changing the salt form of treprostinil did not result
  • the 01-102 study was designed to evaluate and compare the safety and pharmacokinetic profiles of a (1) UT-15C SR tablet prototype and, (2) UT-15C SR capsule prototype (microparticulate beads in a capsule) in both the fasted and fed state.
  • Each of the SR dosage forms weres designed to release UT-15C (1 mg) over an approximate 8-hour time period.
  • Fourteen healthy adult volunteers were assigned to receive the SR tablet formulation while an additional fourteen volunteers were assigned to receive the SR capsule formulation.
  • Subjects were randomized to receive a single dose (1 mg) of their assigned SR prototype in both the fasted and fed state.
  • a crossover design was employed with a seven day wash-out period separating the fed/fasted states.
  • subjects received a high calorie, high fat meal.
  • Study endpoints included standard safety assessments (adverse events, vital signs, laboratory parameters, physical examinations, and electrocardiograms) as well as pharmacokinetic parameters.
  • Form A Two crystalline forms of UT-15C were idenitified as well as an amorphous form.
  • Form B The second, which is thermodynamically more stable, is Form B.
  • Form A is made according to the methods in Table 15.
  • Form B is made from Form A, in accordance with the procedures of Table 16.
  • FE fast evaporation
  • SE slow evaporation
  • SC slow cool
  • IS insufficient sample
  • PO preferred orientation
  • LC low crystallinity
  • pk peak c
  • XRPD X-ray powder diffraction
  • the initial material synthesized (termed Form A) was characterized using X- ray powder diffraction (XRPD), differential scanning calorimetry (DSC), thermogravimetry (TG), hot stage microscopy, infrared (IR) and Raman spectroscopy, and moisture sorption.
  • Representative XRPD of Form A is shown in Figure 15.
  • the IR and Raman spectra for Form A are shown in Figures 16 and 17, respectively.
  • the thermal data for Form A are shown in Figure 18.
  • the DSC thennogram shows an endotherm at 103 °C that is consistent with melting (from hot stage microscopy). The sample was observed to recrystallize to needles on cooling from the melt.
  • the TG data shows no measurable weight loss up to 100 °C, indicating that the material is not solvated.
  • the moisture sorption data are shown graphically in Figure 19.
  • Form A material shows significant weight gain (>33%) during the course of the experiment (beginning between 65 to 75% RH), indicating that the material is hygroscopic, hi addition, hygroscopicity of freprostinil diethanolamine was evaluated in humidity chambers at approximately 52% RH and 68% RH. The materials were observed to gain 4.9% and 28% weight after 23 days in the -52% RH and ⁇ 68% RH chambers, respectively.
  • Form A is a crystalline, anhydrous material which is hygroscopic and melts at 103 °C.
  • Treprostinil diethanolamine Form B was made from heated slurries (50 °C) of Form A in 1,4 dioxane and toluene, as shown in Table 16. Material isolated from 1 ,4- dioxane was used to fully characterize Fo ⁇ n B. A representative XRPD pattern of Form B is shown in Figure 20. Form A and Form B XRPD patterns are similar,
  • the thermal data for Form B are shown in Figure 21.
  • the DSC thermogram (Sample ID 1557-17-01) shows a single endotherm at 107 °C that is consistent with a melting event (as determined by hotstage microscopy).
  • the TG shows minimal weight loss up to 100 °C.
  • Form A and Form B can easily be detected in the DSC curve. Based on the above characterization data, Form B appears to be a crystalline material which melts at l07 °C.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP04776104.4A 2003-05-22 2004-05-24 Verbindungen und verfahren zur abgabe von prostacyclin-analoga Expired - Lifetime EP1628654B2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP14162471.8A EP2792353B1 (de) 2003-05-22 2004-05-24 Polymorph von Treprostinil-Diethanolaminsalz

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47240703P 2003-05-22 2003-05-22
PCT/US2004/016401 WO2005007081A2 (en) 2003-05-22 2004-05-24 Compounds and methods for delivery of prostacyclin analogs

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP14162471.8A Division EP2792353B1 (de) 2003-05-22 2004-05-24 Polymorph von Treprostinil-Diethanolaminsalz
EP14162471.8A Division-Into EP2792353B1 (de) 2003-05-22 2004-05-24 Polymorph von Treprostinil-Diethanolaminsalz

Publications (4)

Publication Number Publication Date
EP1628654A2 true EP1628654A2 (de) 2006-03-01
EP1628654A4 EP1628654A4 (de) 2008-10-15
EP1628654B1 EP1628654B1 (de) 2017-01-25
EP1628654B2 EP1628654B2 (de) 2019-12-04

Family

ID=34079029

Family Applications (2)

Application Number Title Priority Date Filing Date
EP04776104.4A Expired - Lifetime EP1628654B2 (de) 2003-05-22 2004-05-24 Verbindungen und verfahren zur abgabe von prostacyclin-analoga
EP14162471.8A Expired - Lifetime EP2792353B1 (de) 2003-05-22 2004-05-24 Polymorph von Treprostinil-Diethanolaminsalz

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP14162471.8A Expired - Lifetime EP2792353B1 (de) 2003-05-22 2004-05-24 Polymorph von Treprostinil-Diethanolaminsalz

Country Status (8)

Country Link
US (19) US7417070B2 (de)
EP (2) EP1628654B2 (de)
JP (2) JP5043433B2 (de)
KR (1) KR101072339B1 (de)
CN (4) CN101780092B (de)
CA (4) CA2959852A1 (de)
ES (2) ES2622471T5 (de)
WO (1) WO2005007081A2 (de)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016055819A1 (en) 2014-10-08 2016-04-14 CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. Process for the preparation of treprostinil
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9701616B2 (en) 2015-06-17 2017-07-11 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9776982B2 (en) 2013-01-11 2017-10-03 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US9845305B2 (en) 2013-01-11 2017-12-19 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10214983A1 (de) * 2002-04-04 2004-04-08 TransMIT Gesellschaft für Technologietransfer mbH Vernebelbare Liposomen und ihre Verwendung zur pulmonalen Applikation von Wirkstoffen
CN101780092B (zh) 2003-05-22 2012-07-04 联合治疗公司 化合物和释放前列环素类似物的方法
WO2005058303A1 (en) * 2003-12-16 2005-06-30 United Therapeutics Corporation Use of treprostinil to treat and prevent ischemic lesions
US20090124697A1 (en) 2003-12-16 2009-05-14 United Therapeutics Corporation Inhalation formulations of treprostinil
KR20060123482A (ko) * 2003-12-16 2006-12-01 유나이티드 쎄러퓨틱스 코포레이션 신장 기능을 개선하기 위한 트레프로스티닐의 용도
ES2340939T3 (es) 2004-04-12 2010-06-11 United Therapeutics Corporation Utilizacioin del treprostinil para tratar las ulceras de pie diabeticas neuropaticas.
KR20080029962A (ko) * 2005-06-02 2008-04-03 더 리젠츠 오브 더 유니버시티 오브 콜로라도 프로스타사이클린 유사체의 용도
US8747897B2 (en) 2006-04-27 2014-06-10 Supernus Pharmaceuticals, Inc. Osmotic drug delivery system
CN101495122B (zh) 2006-05-15 2011-10-05 联合治疗公司 使用定量吸入器给予曲前列尼
DE102006026786A1 (de) 2006-06-07 2007-12-13 Joachim Kern Dosierinhalator
US20090036465A1 (en) * 2006-10-18 2009-02-05 United Therapeutics Corporation Combination therapy for pulmonary arterial hypertension
WO2008088617A1 (en) * 2006-12-04 2008-07-24 Regents Of The University Of Colorado Treatment of copd
EP2120961A1 (de) 2007-02-09 2009-11-25 United Therapeutics Corporation Treprostinil-behandlung für interstitielle lungenerkrankungen und asthma
KR101614465B1 (ko) * 2007-12-17 2016-04-21 유나이티드 세러퓨틱스 코오포레이션 레모둘린?의 활성 성분인 트레프로스티닐의 개선된 제조 방법
US8350079B2 (en) * 2008-05-08 2013-01-08 United Therapeutics Corporation Treprostinil formulation
US20110294815A1 (en) * 2008-06-27 2011-12-01 Harbeson Scott L Prostacyclin analogs
KR101544246B1 (ko) * 2009-05-07 2015-08-12 유나이티드 세러퓨틱스 코오포레이션 프로스타시클린 유사체의 고체 제제
CN101891596B (zh) * 2009-05-22 2013-12-11 上海天伟生物制药有限公司 一种化合物及其制备方法和用途
DE102009031274A1 (de) 2009-06-30 2011-01-13 Justus-Liebig-Universität Giessen Liposomen zur pulmonalen Applikation
US20120184622A1 (en) * 2009-08-07 2012-07-19 Scipharm Sarl Composition for the treatment of cystic fibrosis
ES2611187T3 (es) 2010-03-15 2017-05-05 United Therapeutics Corporation Tratamiento para hipertensión pulmonar
US8481782B2 (en) 2010-06-03 2013-07-09 United Therapeutics Corporation Treprostinil production
EP2582235A4 (de) * 2010-06-15 2014-04-30 United Therapeutics Corp Orale behandlung ischämischer läsionen der finger
CA2710725C (en) 2010-07-22 2017-08-01 Alphora Research Inc. Protected aldehydes for use as intermediates in chemical syntheses, and processes for their preparation
CA2726599C (en) 2010-12-30 2017-07-25 Alphora Research Inc. Process for treprostinil salt preparation
US10920242B2 (en) 2011-02-25 2021-02-16 Recombinetics, Inc. Non-meiotic allele introgression
US8461393B2 (en) 2011-03-02 2013-06-11 United Therapeutics Corporation Synthesis of intermediate for treprostinil production
CN103193626B (zh) 2012-01-10 2016-05-11 上海天伟生物制药有限公司 一种前列腺素类似物的晶型及其制备方法和用途
CN103193627B (zh) 2012-01-10 2016-04-20 上海天伟生物制药有限公司 一种前列腺素类似物的晶型及其制备方法和用途
US9387214B2 (en) 2012-01-13 2016-07-12 United Therapeutics Corporation Method of identifying therapies for pulmonary hypertension
SI2674413T1 (sl) * 2012-06-15 2017-10-30 Scipharm Sarl Postopek za pripravo treprostinila in derivatov le-tega
KR20150089087A (ko) * 2012-11-30 2015-08-04 인스메드 인코포레이티드 프로스타사이클린 조성물 및 이를 이용하기 위한 방법
TWI634104B (zh) * 2012-12-07 2018-09-01 凱曼化學有限公司 前列環素（ｐｒｏｓｔａｃｙｃｌｉｎ）類似物之合成方法
CN103880801B (zh) * 2012-12-20 2017-11-03 江苏盛迪医药有限公司 一种制备曲前列尼尔的中间体、其制备方法以及通过其制备曲前列尼尔的方法
EP2970091A4 (de) 2013-03-14 2017-02-08 United Therapeutics Corporation Feste formen von treprostinil
WO2014150203A1 (en) * 2013-03-15 2014-09-25 United Therapeutics Corporation Salts of treprostinil
JP6263604B2 (ja) 2013-03-25 2018-01-17 ユナイテッド セラピューティクス コーポレイション チオールリンカーを持つ、ペグ化型のプロスタサイクリン化合物の製造方法
CA2911172C (en) 2013-04-30 2021-10-19 United Therapeutics Corporation Controlled release pharmaceutical formulations
PT3060041T (pt) * 2013-10-25 2021-03-12 Insmed Inc Compostos de prostaciclina
US9895465B2 (en) 2014-03-12 2018-02-20 Pioneer Surgical Technology, Inc. Absorbable compositions and methods for their use in hemostasis
WO2015192030A1 (en) 2014-06-13 2015-12-17 United Therapeutics Corporation Treprostinil formulations
JP6561109B2 (ja) * 2014-07-16 2019-08-14 コルセア ファーマ インコーポレイテッド トレプロスチニル誘導体化合物およびその使用方法
WO2016038532A1 (en) 2014-09-09 2016-03-17 Mylan Laboratories Limited Amorphous treprostinil diethanolamine
US9593061B2 (en) 2014-10-20 2017-03-14 United Therapeutics Corporation Synthesis of intermediates for producing prostacyclin derivatives
ES2873873T3 (es) * 2014-11-18 2021-11-04 Insmed Inc Métodos de fabricación de treprostinilo y profármacos derivados de treprostinilo
TWI540121B (zh) * 2014-12-01 2016-07-01 臺灣永光化學工業股份有限公司 曲前列環素二乙醇胺之合成方法及新穎中間體
CA2967899C (en) 2014-12-03 2023-09-19 Steadymed Ltd Preservative-free treprostinil formulations and methods and devices for use with same
CN104783298A (zh) * 2015-03-24 2015-07-22 湖州珍贝羊绒制品有限公司 一种生物灭菌组合物及其纳米乳的制备与应用
WO2016176555A1 (en) * 2015-04-29 2016-11-03 Insmed Incorporated Prostacyclin compounds, compositions and methods of use thereof
US11069054B2 (en) 2015-12-30 2021-07-20 Visiongate, Inc. System and method for automated detection and monitoring of dysplasia and administration of immunotherapy and chemotherapy
ES2933175T3 (es) * 2016-09-15 2023-02-02 Camurus Ab Formulaciones de análogos de prostaciclina
WO2018058124A1 (en) 2016-09-26 2018-03-29 United Therapeutics Corporation Treprostinil prodrugs
KR20190109399A (ko) 2016-12-05 2019-09-25 코세어 파마 인코포레이티드 트레프로스티닐 및 이의 염의 피부 및 경피 투여
US10799653B2 (en) 2017-01-09 2020-10-13 United Therapeutics Corporation Aerosol delivery device and method for manufacturing and operating the same
EP3498283A1 (de) 2017-12-14 2019-06-19 Ipsol AG Glycosidische derivate von treprostinil
HU231296B1 (hu) 2018-03-09 2022-09-28 Chinoin Zrt Eljárás treprostinil-dietanol-amin só B polimorf formájának előállítására
EP3790554A4 (de) * 2018-05-07 2022-03-30 Pharmosa Biopharm Inc. Pharmazeutische zusammensetzung zur kontrollierten freisetzung von treprostinil
WO2020060823A1 (en) 2018-09-18 2020-03-26 Eli Lilly And Company Erbumine salt of treprostinil
BR112021021775A2 (pt) * 2019-04-29 2022-01-04 Insmed Inc Composições de pó seco de pró-fármacos de treprostinil e métodos de uso destas
JP2020011957A (ja) * 2019-07-22 2020-01-23 コルセア ファーマ インコーポレイテッド トレプロスチニル誘導体化合物およびその使用方法
CA3149358A1 (en) * 2019-08-23 2021-03-04 United Therapeutics Corporation Treprostinil prodrugs
US10781160B1 (en) * 2019-10-04 2020-09-22 Chirogate International Inc. Hexadecyl Treprostinil crystals and methods for preparation thereof
CA3161960A1 (en) 2019-12-16 2021-06-24 Tenax Therapeutics, Inc. Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (ph-hfpef)
EP4135707A1 (de) 2020-04-17 2023-02-22 United Therapeutics Corporation Treprostinil zur verwendung bei der behandlung von intersitiellen lungenerkrankungen
CA3180230A1 (en) 2020-06-09 2021-12-16 Hitesh Batra Fumaryl diketopiperidine prodrugs of treprostinil
JP7138685B2 (ja) * 2020-10-26 2022-09-16 コルセア ファーマ インコーポレイテッド トレプロスチニル誘導体化合物およびその使用方法
US11447440B2 (en) 2020-10-29 2022-09-20 Chirogate International Inc. Treprostinil monohydrate crystals and methods for preparation thereof
CA3202061A1 (en) 2020-12-14 2022-06-23 Kenneth Robert Phares Methods of treating disease with treprostinil prodrugs
WO2022187352A1 (en) 2021-03-03 2022-09-09 United Therapeutics Corporation A dry powder composition of trestinil and its prodrug thereof and further comprising comprising (e)-3,6-bis[4-(n-carbonyl-2-propenyl)amidobutyl]-2,5-diketopiperazine (fdkp)
CN113552265B (zh) * 2021-09-17 2022-01-04 天地恒一制药股份有限公司 富马酸丙酚替诺福韦合成原料中杂质的检测方法及应用
US20230263807A1 (en) 2022-02-08 2023-08-24 United Therapeutics Corporation Treprostinil iloprost combination therapy
US20240139207A1 (en) 2022-10-31 2024-05-02 United Therapeutics Corporation Methods for treating pulmonary hypertension
WO2024155752A1 (en) 2023-01-19 2024-07-25 United Therapeutics Corporation Treprostinil analogs

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2070596A (en) * 1980-02-28 1981-09-09 Upjohn Co Carbacyclin Analogues
WO2000057701A1 (en) * 1999-03-31 2000-10-05 United Therapeutics Corporation Prostaglandin compounds, compositions and methods of treating peripheral vascular disease and pulmonary hypertension
WO2003049676A2 (en) * 2001-12-10 2003-06-19 United Therapeutics Corporation Modified prostaglandin compounds and analogs thereof, compositions containing the same useful for the teatment of cancer

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US515322A (en) * 1894-02-27 Railroad-car
US3515222A (en) * 1968-06-19 1970-06-02 American Tractor Equip Corp Cable plow mounting
US4490537A (en) 1977-04-19 1984-12-25 The Upjohn Company Enlarged-hetero-ring prostacyclin analogs
US4525586A (en) 1980-02-28 1985-06-25 The Upjohn Company Composition and process
US4338457A (en) 1980-02-28 1982-07-06 The Upjohn Company Composition and process
US4306075A (en) 1980-03-28 1981-12-15 The Upjohn Company Composition and process
US4420632A (en) 1980-04-15 1983-12-13 The Upjohn Company Composition and process
US4306076A (en) 1980-04-23 1981-12-15 The Upjohn Company Inter-phenylene CBA compounds
US4349689A (en) * 1980-12-22 1982-09-14 The Upjohn Company Methano carbacyclin analogs
US4434164A (en) 1981-06-01 1984-02-28 Pfizer Inc. Crystalline benzothiazine dioxide salts
US4486598A (en) 1982-02-22 1984-12-04 The Upjohn Company Carbacyclin analogs
DE3315356A1 (de) 1982-04-30 1983-11-17 Ono Pharmaceutical Co. Ltd., Osaka Verwendung von prostaglandinanalogen
US4561604A (en) 1983-07-18 1985-12-31 Shimano Industrial Company Limited Spinning reel
FI67490C (fi) 1983-11-02 1985-04-10 Fluilogic Systems Oy Filtreringsenhet
US4744989A (en) 1984-02-08 1988-05-17 E. R. Squibb & Sons, Inc. Method of preparing liposomes and products produced thereby
US4683330A (en) 1984-03-08 1987-07-28 The Upjohn Company Interphenylene carbacyclin derivatives
CA1241324A (en) 1984-03-08 1988-08-30 Paul A. Aristoff Interphenylene carbacyclin derivatives
US4668814A (en) * 1984-03-08 1987-05-26 The Upjohn Company Interphenylene carbacyclin derivatives
DE3448257C2 (en) 1984-07-25 1988-08-18 Schering Ag, 1000 Berlin Und 4709 Bergkamen, De Cytoprotective action of prostacyclin derivatives on the kidney
US5663203A (en) 1986-09-11 1997-09-02 Schering Aktiengesellschaft Agents containing prostacyclin derivatives for topical application
GB8824187D0 (en) 1988-10-14 1988-11-23 Wellcome Found Compounds for use in medicine
GB8814438D0 (en) 1988-06-17 1988-07-20 Wellcome Found Compounds for use in medicine
US5545671A (en) * 1989-10-05 1996-08-13 Schering Aktiengesellschaft Antimetastically acting agents
GB9011588D0 (en) * 1990-05-24 1990-07-11 Wellcome Found Prostaglandin analogues for use in medicine
DE4104606C1 (de) 1991-02-12 1992-10-15 Schering Ag Berlin Und Bergkamen, 1000 Berlin, De
US5496850A (en) * 1991-04-11 1996-03-05 Toray Industries, Inc. Antimetastasis agent of malignant tumors
DE4135193C1 (de) 1991-10-22 1993-03-11 Schering Ag Berlin Und Bergkamen, 1000 Berlin, De
US5190972A (en) 1992-01-27 1993-03-02 The University Of Melbourne Method of combatting cyclosporine organ toxicity with prostaglandin analogs
DE4202665A1 (de) 1992-01-28 1993-07-29 Schering Ag Prostacyclin- und carbacyclinderivate als mittel zur behandlung von multipler sklerose
US6171786B1 (en) 1992-09-17 2001-01-09 Board Of Trustees Of University Of Illinois Methods for preventing multidrug resistance in cancer cells
US5466203A (en) * 1994-03-30 1995-11-14 Chen; George Magnetically controlled load adjusting structure of gymnastic apparatus
AU721653B2 (en) 1996-10-25 2000-07-13 Supernus Pharmaceuticals, Inc. Soluble form osmotic dose delivery system
US6656502B1 (en) 1997-03-14 2003-12-02 Toray Industries, Inc. Sustained-release prostaglandin I derivative preparation
US6451815B1 (en) 1997-08-14 2002-09-17 Aventis Pharmaceuticals Inc. Method of enhancing bioavailability of fexofenadine and its derivatives
GB9718903D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US6441245B1 (en) 1997-10-24 2002-08-27 United Therapeutics Corporation Process for stereoselective synthesis of prostacyclin derivatives
DK1025083T3 (da) 1997-10-24 2004-03-01 United Therapeutics Corp Fremgangsmåde til stereoselektiv syntese af prostacyclin-derivater
DE69822665T2 (de) * 1997-11-14 2005-02-17 United Therapeutics Corp. Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14-dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen
US20010038855A1 (en) 1998-06-05 2001-11-08 Desjardin Michael A. Dosage form for administering prescribed dose
US6706283B1 (en) 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
AU3934000A (en) * 1999-03-18 2000-10-04 United Therapeutics Corporation Inhibitors of endothelin-1 synthesis
US6521212B1 (en) 1999-03-18 2003-02-18 United Therapeutics Corporation Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation
US6570013B2 (en) 2000-02-16 2003-05-27 Pfizer Inc Salts of zopolrestat
US6242482B1 (en) * 2000-06-05 2001-06-05 United Therapeutics Corporation Prostaglandin compounds and derivatives thereof, compositions containing the same and method of using the same for the treatment of congestive heart failure
CA2417973A1 (en) * 2000-08-04 2002-02-14 Longwood Pharmaceutical Research, Inc. Formulations of mometasone and a bronchodilator for pulmonary administration
US20020090388A1 (en) 2000-12-01 2002-07-11 Humes H. David Intravascular drug delivery device and use therefor
US6700025B2 (en) 2001-01-05 2004-03-02 United Therapeutics Corporation Process for stereoselective synthesis of prostacyclin derivatives
US6803386B2 (en) * 2002-01-16 2004-10-12 United Therapeutics Corporation Prostacyclin derivative containing compositions and methods of using the same for the treatment of cancer
US7132453B2 (en) 2002-03-15 2006-11-07 Vanderbilt University Method of using prostacyclin to treat respiratory syncytial virus infections
DE10214983A1 (de) 2002-04-04 2004-04-08 TransMIT Gesellschaft für Technologietransfer mbH Vernebelbare Liposomen und ihre Verwendung zur pulmonalen Applikation von Wirkstoffen
CN101780092B (zh) * 2003-05-22 2012-07-04 联合治疗公司 化合物和释放前列环素类似物的方法
US20050101608A1 (en) 2003-09-24 2005-05-12 Santel Donald J. Iloprost in combination therapies for the treatment of pulmonary arterial hypertension
US20050254032A1 (en) 2003-11-13 2005-11-17 Fuji Photo Film Co., Ltd. Exposure device
WO2005058303A1 (en) 2003-12-16 2005-06-30 United Therapeutics Corporation Use of treprostinil to treat and prevent ischemic lesions
EP2120961A1 (de) 2007-02-09 2009-11-25 United Therapeutics Corporation Treprostinil-behandlung für interstitielle lungenerkrankungen und asthma
KR101614465B1 (ko) * 2007-12-17 2016-04-21 유나이티드 세러퓨틱스 코오포레이션 레모둘린?의 활성 성분인 트레프로스티닐의 개선된 제조 방법
US8350079B2 (en) * 2008-05-08 2013-01-08 United Therapeutics Corporation Treprostinil formulation
JP2010244388A (ja) * 2009-04-08 2010-10-28 Pioneer Electronic Corp 情報提供装置、情報提供方法、及び情報提供用プログラム
KR101544246B1 (ko) 2009-05-07 2015-08-12 유나이티드 세러퓨틱스 코오포레이션 프로스타시클린 유사체의 고체 제제
US8481782B2 (en) * 2010-06-03 2013-07-09 United Therapeutics Corporation Treprostinil production

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2070596A (en) * 1980-02-28 1981-09-09 Upjohn Co Carbacyclin Analogues
WO2000057701A1 (en) * 1999-03-31 2000-10-05 United Therapeutics Corporation Prostaglandin compounds, compositions and methods of treating peripheral vascular disease and pulmonary hypertension
WO2003049676A2 (en) * 2001-12-10 2003-06-19 United Therapeutics Corporation Modified prostaglandin compounds and analogs thereof, compositions containing the same useful for the teatment of cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2005007081A2 *

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10344012B2 (en) 2013-01-11 2019-07-09 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US11958822B2 (en) 2013-01-11 2024-04-16 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US9776982B2 (en) 2013-01-11 2017-10-03 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US9845305B2 (en) 2013-01-11 2017-12-19 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US11505535B2 (en) 2013-01-11 2022-11-22 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US11339139B2 (en) 2013-01-11 2022-05-24 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US10752605B2 (en) 2013-01-11 2020-08-25 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US10450290B2 (en) 2013-01-11 2019-10-22 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US11046666B2 (en) 2013-01-11 2021-06-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US11724979B2 (en) 2014-10-08 2023-08-15 CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. Process for the preparation of treprostinil
WO2016055819A1 (en) 2014-10-08 2016-04-14 CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. Process for the preparation of treprostinil
US10322990B2 (en) 2014-10-08 2019-06-18 CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. Process for the preparation of treprostinil
US11098001B2 (en) 2014-10-08 2021-08-24 CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. Process for the preparation of treprostinil
US10053414B2 (en) 2015-06-17 2018-08-21 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US10246403B2 (en) 2015-06-17 2019-04-02 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US10759733B2 (en) 2015-06-17 2020-09-01 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US10988435B2 (en) 2015-06-17 2021-04-27 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US11034645B2 (en) 2015-06-17 2021-06-15 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US10464878B2 (en) 2015-06-17 2019-11-05 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US10464877B2 (en) 2015-06-17 2019-11-05 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US10703706B2 (en) 2015-06-17 2020-07-07 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US11407707B2 (en) 2015-06-17 2022-08-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9957220B2 (en) 2015-06-17 2018-05-01 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9701616B2 (en) 2015-06-17 2017-07-11 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US11802105B2 (en) 2015-06-17 2023-10-31 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US11866402B2 (en) 2015-06-17 2024-01-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof

Also Published As

Publication number Publication date
US20130261187A1 (en) 2013-10-03
EP1628654A4 (de) 2008-10-15
JP2007501281A (ja) 2007-01-25
US11292758B2 (en) 2022-04-05
EP2792353B1 (de) 2018-02-28
US20180141891A1 (en) 2018-05-24
US20070082948A1 (en) 2007-04-12
US20200181057A1 (en) 2020-06-11
KR20060021862A (ko) 2006-03-08
CA2526534A1 (en) 2005-01-27
US9199908B2 (en) 2015-12-01
US9624156B2 (en) 2017-04-18
US20050085540A1 (en) 2005-04-21
CA2736406A1 (en) 2005-01-27
US7544713B2 (en) 2009-06-09
US9878972B2 (en) 2018-01-30
CA2736406C (en) 2014-11-18
CN101780092A (zh) 2010-07-21
US20190345091A1 (en) 2019-11-14
KR101072339B1 (ko) 2011-10-11
US20110118213A1 (en) 2011-05-19
CA2851309C (en) 2017-04-18
CN101265226A (zh) 2008-09-17
CN101780092B (zh) 2012-07-04
WO2005007081A2 (en) 2005-01-27
US8536363B2 (en) 2013-09-17
ES2622471T3 (es) 2017-07-06
CN1822826A (zh) 2006-08-23
US8232316B2 (en) 2012-07-31
CA2851309A1 (en) 2005-01-27
WO2005007081A3 (en) 2005-04-14
EP2792353A2 (de) 2014-10-22
WO2005007081A9 (en) 2017-01-26
US20150005374A1 (en) 2015-01-01
US7417070B2 (en) 2008-08-26
US20160355455A1 (en) 2016-12-08
CN100558351C (zh) 2009-11-11
US20070078095A1 (en) 2007-04-05
CA2959852A1 (en) 2005-01-27
CN101265226B (zh) 2013-04-24
EP1628654B2 (de) 2019-12-04
US8410169B2 (en) 2013-04-02
US9050311B2 (en) 2015-06-09
CN102697790A (zh) 2012-10-03
EP1628654B1 (de) 2017-01-25
ES2622471T5 (es) 2020-07-23
US20220289660A1 (en) 2022-09-15
US20150259274A1 (en) 2015-09-17
JP2012162539A (ja) 2012-08-30
CA2526534C (en) 2011-07-12
US7384978B2 (en) 2008-06-10
EP2792353A3 (de) 2015-03-25
US9278901B2 (en) 2016-03-08
US20220024845A1 (en) 2022-01-27
US20160051505A1 (en) 2016-02-25
US8252839B2 (en) 2012-08-28
US9422223B2 (en) 2016-08-23
JP5043433B2 (ja) 2012-10-10
US20080249167A1 (en) 2008-10-09
US20070078182A1 (en) 2007-04-05
US20050282901A1 (en) 2005-12-22
ES2670872T3 (es) 2018-06-01
US20160030371A1 (en) 2016-02-04
US20120295980A1 (en) 2012-11-22
US10947177B2 (en) 2021-03-16

Similar Documents

Publication Publication Date Title
US20220289660A1 (en) Compounds and methods for delivery of prostacyclin analogs

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20051220

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20080912

17Q First examination report despatched

Effective date: 20110308

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602004050699

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: A61K0031190000

Ipc: C07C0059700000

RIC1 Information provided on ipc code assigned before grant

Ipc: C07C 259/06 20060101ALI20160708BHEP

Ipc: A61K 31/215 20060101ALI20160708BHEP

Ipc: C07C 69/712 20060101ALI20160708BHEP

Ipc: C07C 235/08 20060101ALI20160708BHEP

Ipc: A61P 9/00 20060101ALI20160708BHEP

Ipc: C07C 229/08 20060101ALI20160708BHEP

Ipc: C07C 59/70 20060101AFI20160708BHEP

Ipc: C07C 235/06 20060101ALI20160708BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20160822

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

GRAT Correction requested after decision to grant or after decision to maintain patent in amended form

Free format text: ORIGINAL CODE: EPIDOSNCDEC

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 864015

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170215

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602004050699

Country of ref document: DE

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 14

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20170125

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 864015

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170125

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170125

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2622471

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20170706

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170426

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170125

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170125

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170125

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170531

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170425

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170525

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170125

REG Reference to a national code

Ref country code: DE

Ref legal event code: R026

Ref document number: 602004050699

Country of ref document: DE

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170125

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170125

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170125

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170125

26 Opposition filed

Opponent name: TEVA PHARMACEUTICAL INDUSTRIES LTD

Effective date: 20171025

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170125

PLAX Notice of opposition and request to file observation + time limit sent

Free format text: ORIGINAL CODE: EPIDOSNOBS2

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170125

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170531

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170531

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170125

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170524

PLBB Reply of patent proprietor to notice(s) of opposition received

Free format text: ORIGINAL CODE: EPIDOSNOBS3

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 15

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20170531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170524

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170531

RIC2 Information provided on ipc code assigned after grant

Ipc: C07C 69/712 20060101ALI20190205BHEP

Ipc: C07C 59/13 20060101ALI20190205BHEP

Ipc: C07C 51/41 20060101ALI20190205BHEP

Ipc: A61P 9/00 20060101ALI20190205BHEP

Ipc: C07F 9/09 20060101ALI20190205BHEP

Ipc: A61K 31/235 20060101ALI20190205BHEP

Ipc: C07C 235/06 20060101ALI20190205BHEP

Ipc: A61K 9/00 20060101ALI20190205BHEP

Ipc: A61K 31/215 20060101ALI20190205BHEP

Ipc: C07C 229/08 20060101ALI20190205BHEP

Ipc: A61K 31/216 20060101ALI20190205BHEP

Ipc: C07C 235/08 20060101ALI20190205BHEP

Ipc: A61K 31/223 20060101ALI20190205BHEP

Ipc: A61K 31/192 20060101ALI20190205BHEP

Ipc: C07F 9/117 20060101ALI20190205BHEP

Ipc: C07C 59/70 20060101AFI20190205BHEP

Ipc: C07C 259/06 20060101ALI20190205BHEP

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20040524

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170125

PUAH Patent maintained in amended form

Free format text: ORIGINAL CODE: 0009272

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: PATENT MAINTAINED AS AMENDED

27A Patent maintained in amended form

Effective date: 20191204

AK Designated contracting states

Kind code of ref document: B2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: DE

Ref legal event code: R102

Ref document number: 602004050699

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170125

REG Reference to a national code

Ref country code: ES

Ref legal event code: DC2A

Ref document number: 2622471

Country of ref document: ES

Kind code of ref document: T5

Effective date: 20200723

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20230330

Year of fee payment: 20

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230509

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20230412

Year of fee payment: 20

Ref country code: FR

Payment date: 20230411

Year of fee payment: 20

Ref country code: ES

Payment date: 20230605

Year of fee payment: 20

Ref country code: DE

Payment date: 20230331

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 602004050699

Country of ref document: DE

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20240531

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20240523

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20240523

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20240525

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20240523

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20240525